ii  Extracorporeal CPR for Refractory Out -of-Hospi[INVESTIGATOR_23060] (EROCA) IDE  
Principal Investigator: [INVESTIGATOR_503678], MD, PhD I  
ND/IDE Sponsor: Robert Neumar, MD, PhD Funded by: [CONTACT_74379]  
04/15/2019  
[STUDY_ID_REMOVED]  
  
iii  EROCA – IDE Protocol  Version  0.[ADDRESS_648388] OF  ABBREVIATIONS ........................................................................................................................... 1 
STATEMENT OF  COMPLIANCE  ................................................................................................................. 2 
PROTOCOL  SUMMARY  ............................................................................................................................... 3 
SCHEMATIC OF  STUDY  DESIGN  ............................................................................................................... 5 
KEY ROLES  .................................................................................................................................................. 6 
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC  RATIONALE  ...................... 7 
2.1 Background Information  ...................................................................................  …………….    7  
2.1.1  CLINICAL SIGNIFICANCE  .................................................................................... 7 
2.1.2  RELEVANT CLINICAL RESEARCH  ...................................................................... 8 
2.2 Rationale  .................................................................................................................................. 9 
2.3 Potential Risks  and Benefits  .................................................................................................... 9 
2.3.1  Known Potential  Risks  ........................................................................................... 9 
2.3.2  Known Potential  Benefits  ..................................................................................... 10 
3 OBJECTIVES AND PURPOSE  ....................................................................................................... 10 
4 STUDY DESIGN AND ENDPOI NTS ............................................................................................... 11 
4.1 Description of the Study  Design  ............................................................................................ 11 
4.2.2  SAFETY  Endpoints  .............................................................................................. 11 
4.2.3  Exploratory  Endpoints  .......................................................................................... 12 
5 STUDY ENROLLMENT AND  WITHDRAWAL  ................................................................................. 12 
5.1 Inclusion Criteria  .................................................................................................................... 12  
5.1.1  Patient level  INCLUSION  ............................................................................................................ 12 
5.1.2  Included EMS AGENCIES / REGIONS / HOSPI[INVESTIGATOR_281593]  ............................................................... 12 
5.2 Participant  Exclusion  Criteria  ................................................................................................. 13 
5.3 Strategies for Recruitment  and Retention  .............................................................................. 13 
5.4 Participant Withdrawal  or termination  .................................................................................... 15 
5.4.1  Reasons for Withdrawal  or Termination  ............................................................... 15 
5.4.2  Handling of Participant Withdrawals  or termination  ............................................. 15 
5.5 Premature Termination or Suspension of Study  .................................................................... 15 
6 STUDY  INTERVENTION ................................................................................................................. 16 
7 STUDY PROCEDURES  AND SCHEDULE  ..................................................................................... 16 
7.1 Study  Procedures/Evaluations  ............................................................................................... [ADDRESS_648389] care study  procedures  .......................................................................... 17 
7.2 Laboratory  Procedures/Evaluations  ....................................................................................... 18 
7.2.1  Clinical Laboratory  Evaluations  ............................................................................ 18 
7.3 Study  Schedule  ...................................................................................................................... 18 
7.3.1  Screening  ............................................................................................................. 18 
7.3.2  Enrollment/Baseline  ............................................................................................. 18 
7.3.3  Follow -up .............................................................................................................. 21 
7.3.4  Final Study  Visit ................................................................................................ ... 21  
7.3.5  Early  Termination Visit  ......................................................................................... 21 
7.3.7  Schedule of  Events  Table  .................................................................................... 21 
7.4 Justification for  Sensitive Procedures  .................................................................................... 22 
7.5 Concomitant Medications, T reatments,  and Procedures  ....................................................... 22 
8 ASSESSMENT OF  SAFETY  ........................................................................................................... 22 
8.1 Specification of  Safety  Parameters  ........................................................................................ 22 
8.1.1  Definition of Adverse  Events  (AE) ....................................................................... 23 
iv 
 EROCA – IDE Protocol  Version  0.03  
8.1.2  Definition of Serious Adverse Events  (SAE)  ........................................................ 23 
8.1.3  Definition of Unanticipated  Problems  (UP) .......................................................... [ADDRESS_648390]  .................................................................................... 29 
8.4.5  Reporting of  Pregnancy  ....................................................................................... 29 
8.5 Study  Halting  Rules  ............................................................................................................... 29 
8.6 Safety  Oversight  .................................................................................................................... 29 
9 CLINICAL  MONITORING  ................................................................................................................ 29 
10 STATISTICAL CONSIDERATIONS  ................................................................................................ 30 
10.1 Statistical and  Analytical  Plans  .............................................................................................. 30 
10.2 Statistical Hypotheses  ............................................................................................................ 30 
10.3 Analysis  Datasets  .................................................................................................................. 30 
10.4 Description of  Statistical Methods  .......................................................................................... 30 
10.4.1  General  Approach  ................................................................................................ 31 
10.4.2  Analysis of the Primary  Efficacy  Endpoint(s)  ....................................................... 31 
10.4.3  Analysis of the Secondary  Endpoint(s)  ................................................................ 31 
10.4.4  Safety  Analyses  ................................................................................................... 31 
10.4.5  Adherence and Retention Analyses  ..................................................................... 31 
10.4.6  Baseline Descriptive Statistics  ............................................................................. 32 
10.4.7  Planned Interim  Analyses  .................................................................................... 32 
10.4.9  Multiple  Comparison/Multiplicity  ........................................................................... 32 
10.4.10  Tabulation of Individual  Response Data  .............................................................. 32 
10.4.11  Exploratory  Analyses  ........................................................................................... 33 
10.5 Sample Size ........................................................................................................................... 33 
10.6 Measures to Minimize  Bias .................................................................................................... 33 
10.6.1  Enrollment/ Randomization/  Masking Procedures  ................................ ............... 33 
10.6.2  Evaluation of Success  of Blinding  ........................................................................ 33 
11 SOURCE DOCUMENTS AND ACCESS TO  SOURCE  DATA/DOCUMENTS  ............................... 34 
12 QUALITY ASSURANCE AND QUALITY  CONTROL  ...................................................................... 34 
13 E
THICS/PROTECTION OF  HUMAN SUBJECTS ........................................................................... [ADDRESS_648391]  ..................................................................................................... 36 
13.3 Informed Consent  Process  .................................................................................................... 37 
13.3.1  Consent/assent  and Other  Informational  Documents  Provided to Participants  ... [ADDRESS_648392] KEEPI[INVESTIGATOR_1645]  ................................................................................. 39 
v 
 EROCA – IDE Protocol  Version  0.[ADDRESS_648393]  POLICY  ...................................................................................... 41 
17 LITERATURE  REFERENCES  ............................................................................................... 41 
Appendix A:  EFIC  PLAN  .......................................................................................................................... 46 
Appendix B: UMHS ED  ECPR  GUIDELINES  .......................................................................................... 60 
Appendix C: Washtenaw Livingston cardiac  arrest  guidelines  .................................................... [ADDRESS_648394]  
IB Investigator’s Brochure  
ICH International Conference on Harmonisation  
ICH E6  International Conference on Harmonisation Guidance for Industry, Good  
Clinical Practice: Consolidated Guidance  
ICMJE  International Committee of Medical Journal Editors  
IDE Investigational Device Exemption  
IND Investigational New Drug Application  
IRB Investigational Review Board  
ISO International Organization for Standardization  
LSMEAN  Least -squares Means  
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
MSDS  Material Safety Data Sheet  
NIH National Institutes of Health  
NIH IC  NIH Institute & Center  
OHRP  Office for Human Research Protections  
PI [INVESTIGATOR_503679]  
 
2    STATEMENT  OF  COMPLIANCE   
 
The trial will be conducted in accordance with the ICH E6, the Code of Federal Regulations on 
the Protection of Human Subjects (45 CFR Part 46), and the NHLBI Terms of Award. The 
Principal Investigator [INVESTIGATOR_7433], or changes to the protocol will take 
place without prior agreement from the sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) 
to the trial participants. All personnel involved in the conduct of this study have completed 
Human Subjects Protection Training.  
I agree to ensure that all staff members involved in the conduct of this study are informed about their obligations in meeting the above commitments.  
Principal Investigator: [INVESTIGATOR_108401] W. Neumar, MD, PhD  
 
Signed:    Date:   
Signature  
3    PROTOCOL  SUMMARY   
 
Title:  Extracorporeal  CPR for refractory out -of-hospi[INVESTIGATOR_164132]  
(EROCA)  
Précis:  EROCA is a prospective, randomized, open -label, clinical endpoint  
study comparing standard prehospi[INVESTIGATOR_503680] -of-hospi[INVESTIGATOR_164132] (OHCA) to a 
qualified emergency department capable of performing advanced 
resuscitation including extracorporeal cardiopulmonary resuscitation (ECPR). A maximum total of [ADDRESS_648395] follow up visits at 
90 days to determine functional an d neuro -cognitive  outcomes.  
Objectives:  Co-Primary: Determine what proportion of patients with refractory  
OHCA can be reliably delivered to an ECPR -capable ED within [ADDRESS_648396] (qua lifying OHCA event).  
 Co-Primary: Determine what proportion of patients with ongoing  
refractory cardiac arrest that have ECPR initiated within 30 minutes of ED arrival.  
Safety: To estimate frequency of adverse events associated with study interventions.  
Exploratory: Demonstrate the feasibility of field randomization of patients with refractory OHCA based on estimated time from [ADDRESS_648397] to qualified ED arrival  
Exploratory: To provide preliminary estimates regarding neurological outcomes following this treatment.  
Endpoints  Co-Primary : Time interval from [ADDRESS_648398] to qualified ED arrival in minutes 
Co-Primary : Time interval from qualified ED arrival to ECPR 
initiation in minutes  
Safety: Composite of major hemorrhage (requiring transfusion of 
over 4 units packed red blood cells per incident), arterial thrombosis (stroke, renal infarction, limb ischemia), venous thrombosis (pulmonary embolism or deep venous thrombosis), hemopericard ium (requiring pericardiocentesis), 
pneumothorax(requiring thoracostomy tube placement), or vascular  
injury (causing complete occlusion and/or requiring vascular  
4   procedure).  
Exploratory: Utility weighted modified Rankin Scale at 90 days 
Exploratory: Neuropsychological and cognitive testing using NIH 
toolbox  
Exploratory: Time to vascular access and time to ECPR cannulation  
Population:  Out-of-hospi[INVESTIGATOR_503681] - responders 
who can potentially arrive at a qualified ED in persistent cardiac arrest within [ADDRESS_648399].  
Phase:  2 
Number of Sites  
enrolling participants:   
1 
Description of Study  
Interventions :  Patients in the field will be randomized to either early transport to  
the hospi[INVESTIGATOR_503682] (continued attempts at advanced cardiac life support in the field). Standard clinical procedures in the 
hospi[INVESTIGATOR_503683].  
Study Duration:  30 months  
Participant Duration:  Three months  
5   
 
 
*Return Of Spontaneous Circulation  
 
**Expedited transfer refers to immediately transferring a patient to the hospi[INVESTIGATOR_503684], using mechanical chest compressions.  SCHEMATIC  OF  STUDY DESIGN  

[ADDRESS_648400]. Ann Arbor, MI [ZIP_CODE] -5301 
Phone: (734) 936 -0253  
Email: [EMAIL_9571]  
 
Robert Bartlett, M.D.  
Co-Principal Investigator  
[INVESTIGATOR_503685], Active Eme ritus  
Director, Extracorporeal Circulation Laboratory 
University of Michigan Health System  
B560B MSRB II, SPC 5686 Ann Arbor, MI [ZIP_CODE] -5686 
Phone: 734 -649-3747  
Email: [EMAIL_9572]  
 
William Meurer, MD, MS 
Assistant Professor, Department of Emergency Medicine University of Michigan Health System  
B1-[ADDRESS_648401]. Ann Arbor, MI [ZIP_CODE] -5301 
Phone: (734) 615- 2766  
Email: [EMAIL_9573]  
 
Robert Silbergleit, M.D. Professor, Emergency Medicine [ADDRESS_648402].  
Suite H - 3100  
Ann Arbor, MI [ZIP_CODE] -5700 
Phone: 734 -232-2142  
Email: [EMAIL_9574]  
 
Kelley Kidwell, Ph D 
Research Assistant Professor of Biostatistics  
1415 Washington Heights, SPH II M2525, Ann Arbor, MI [ZIP_CODE] Ann Arbor, MI [ZIP_CODE]  
7  Phone: 734 -764-6724  
[EMAIL_9575]  
 
Jennifer Fowler, RN BSN, CCRC  
Emergency Medicine Research Project Manager 
University of Michigan Health System  
B1-[ADDRESS_648403]. 
Ann Arbor, MI [ZIP_CODE] -5301 
Phone: 734 -647-0574  
Email: [EMAIL_9576]  
 
 
 
 
Approximately 200,[ADDRESS_648404] (OHCA) each year 
in the [LOCATION_002]. The modest improvement in survival rates over the past decade have 
been primarily attributed to better implementation of cardiopulmonary resuscitation (CPR), 
advanced cardiac life support (ACLS), and post -cardiac arrest care. However, no new therapi[INVESTIGATOR_503686] a decade. The result is a plateauing of overall 
survival rates at approximately 10% [Mozaffarian 2015]. Extracorporeal cardiopulmonary 
resuscitation (ECPR) using percutaneous veno -arterial extracorporeal circulation (VA- ECMO) is 
emerging as a feasible and potentially effective resuscitation strategy for non -traumatic OHCA 
patients who fail standard therapy. In published case series, survival rates range from 4 -33%, 
and organ donation as a secondary outcome occurs in 5 -15% of patient s. Despi[INVESTIGATOR_503687], a fundamental barrier to widespread implementation is the fact  that 
efficacy of ECPR for OHCA has yet to be proven in a prospective randomized clinical trial. In 
October of 2015, the International Liaison Co mmittee on Resuscitation (ILCOR) Consensus on 
Science and Treatment Recommendation made the following treatment recommendation: 
We suggest ECPR is a reasonable rescue therapy for selected patients with cardiac arrest when 
initial conventional CPR is failin g in settings where this can be implemented (weak 
recommendation, very -low-quality evidence) [Callaway 2015]. The primary knowledge gap 
listed was: Controlled clinical trials are needed to assess the effect of ECPR versus traditional CPR on clinical outcomes in patients with cardiac arrest . The new AHA guidelines for CPR and 
Emergency Cardiovascular Care published in October 2015 state: There is insufficient evidence to recommend the routine use of ECPR for patients with cardiac arrest. In settings where it  can 
be rapi[INVESTIGATOR_503688], ECPR may be considered for select cardiac arrest patients for whom 
the suspected etiology of the cardiac arrest is potentially reversible during a limited period of 2 INTRODUCTION: BAC KGROUND INFORMATION  AND SCIENTIFIC RATIONALE  
2.1.1   CLINICAL SIGNIFICANCE  
2.1 BACKGROUND  INFORMATION  
8  mechanical cardiorespi[INVESTIGATOR_1413] (Class IIb,  LOE C -LD) [Link 2015]. Thus, the most recent 
consensus of the world’s experts in the field is a call for more evidence in the form of a 
prospective randomized clinical trial.  
 
 
Almost all published case series of successful ECPR for OHCA initiate ECPR in the emergency 
department [Chen 2008, Kagawa 2010, Nagao 2000 and 2010, LeGuen 2011, Morimura 2011,  
Avali 2012, Bellezzo  2012, Johnson 2014, Sakamoto 2014, Stub 2014], The reason for this 
strategy is that the shorter the interval from cardiac arrest onset to initiation of ECPR, the 
better the chance for a favorable outcome. Figure 3 illustrates this relationship in recent OHCA studies (published after 2010) that specifically reported the collapse to ECPR interval 
and survival with good neurologic function for the entire study population. These and similar reports are the basis for our initial targeting of a 911 call to ECPR interval <[ADDRESS_648405] ECMO catheters and initiate ECPR [Johnson 2014]. However, the model has many logistical limitations that make it challenging to initiate ECPR within the therapeutic window, 
and if maintained will be a persistent barrier to widespread  implementation.  
One example of a program that has incorporated emergency medicine physicians into the 
ECPR team that includes cardiologist and cardiothoracic surgeons Sharp Memorial Hospi[INVESTIGATOR_503689] [Bellezzo 2012]. In their published case series, 8 out of 18 OHCA patients that met inclusion/exclusion had ECPR successfully initiated in the ED, and 3/18 had spontaneous ROSC 
befo re ECPR could be initiation. Of the 8 patients successfully treated with ECPR, 5 survived 
with good neurologic function (63%). However ECPR catheters could not be placed in [ADDRESS_648406] fatal complications of cat heter 
placement (aortic dissection and bifemoral vein cannulation). Although these results 
demonstrate feasibility in a US ED, they also emphasize the importance of validated training 
and maintenance of competency for both clinical trial participation and widespread 
implementation.  
2.1.[ADDRESS_648407]  1) Maekawa 2013; 2) Kagawa 2012; 3) Fagnoul 2013; 4)  
Haneya 2012; 5) Nagao 2010; 6) Ava li 2012; 7) Le Guen 2011. Diamonds represent median 
intervals from collapse to ECPR and lines represents range. (Adapted from Fagnoul 2014 table 
2.) 
 
  2.[ADDRESS_648408] onset to maximize the potential therapeutic benefit. Therefore, in 
addition to delivering patients to the ED within 30 minutes, it is essential that our system of 
care is able to initiate ECPR within ≤30 minutes of ED arrival. In a recently published study of 
ED-initiated ECPR, the median time from ECPR team arrival to initiation of ECPR was 20 
minutes [IQR 15 -30 minutes] [Stub 2014]. The goal is to achieve <30- minute arrival to 
cannulation for all patients meeting inclusion/exclusi on criteria for ECPR therapy.  
 
  2.3 POTENTIAL RISKS  AND  BENEFITS   
 
 
Risks of mechanical or traditional CPR: bruising and soreness of the chest is common after 
mechanical or traditional CPR. Pneumothorax and hemopericardium are also possible risks. Rib fractures and solid organ injuries (liver and spleen) are additional potential risks.  
Risk of EMS (early transport): motor vehicle crash during transport to the hospi[INVESTIGATOR_307].  
 
Alternatives to early transport with me chanical CPR: Continued BLS and ACLS at the scene 
with manual or mechanical CPR until ROSC is achieved or resuscitation efforts are terminated 
(current practice).  
2.3.1   KNOWN  POTENTIAL RISKS  
10  Risks of ECPR (standard care procedure in hospi[INVESTIGATOR_307]): vascular injury, limb isch emia, major 
hemorrhage, venous thromboembolism, stroke, renal failure, and infection.  
Alternatives to ECPR for refractory cardiac arrest: An option is to transport patients to the 
interventional cardiology laboratory with ongoing CPR for coronary angiograp hy and PCI if 
indicated. The rationale for this approach is that an acute coronary occlusion is the cause of 
the cardiac arrest and treating that occlusion could result in ROSC. At this time there is less 
evidence to support this approach compared to ED- initiated ECPR followed by [CONTACT_503750].  
Risks of research: improper disclosure or release of personal or medical information.  
 
 
 
The potential benefit of the research to the research subjects in an improved chance of 
survival with good neurologic function. The current practice for patients with refractory OHCA is for EMS providers to cease resuscitation efforts in the field and pronounce the patients 
dead.  Early transport to an ED capable of advanced resuscitation strategies and ECPR has been reported to result in 4 -33% survival with good neurologic function. The potential benefit 
to society is an improved system of care of OHCA that could double overall surviv al rates and 
with widespread implementation save thousands of lives each year in the [LOCATION_002].  
Reported risks for ECPR include hemorrhage, renal replacement therapy for acute kidney 
injury, vascular damage, thromboembolism, thromboembolism, stroke, an d infection. Relative 
to the potential benefit of survival with good neurologic function, these risks seem reasonable.  
 
 
 
 
Co-Primary: To determine what proportion of patients with refractory OHCA can be delivered 
to an ECPR- capable ED within [ADDRESS_648409] (qualifying OHCA event). This is to establish the feasibility of the early transport 
protocol.  
Co-Primary: To determine what proportion of patients can hav e ECPR initiated within 30 
minutes of ED arrival for patients with ongoing refractory OHCA. This is to establish the feasibility of the ED advanced resuscitation protocol in situations where prenotification of the team has occurred by [CONTACT_503751][INVESTIGATOR_503690].  
Safety: To estimate frequency of adverse events associated with study interventions. This 
early phase trial is not adequately sized to provide meaningful comparative estimates. The  
2.3.2   KNOWN  POTENTIAL BENEFITS  
3 OBJECTIVES  AND  PURPOSE  
11  population of OHCA survivors is at high risk for death and adverse experiences under routine 
clinical care.  
Exploratory: Demonstrate the feasibility of field randomization of patients with refractory 
OHCA. This study is using a novel procedure to determine eligibility based on timing and 
locatio n. 
Exploratory: We will collect ECPR process measures including time to confirmed vascular access and confirmed ECPR cannulation. These measures are collected as part of routine 
clinical care on all patients undergoing ECPR for cardiac arrest at the qualif ied emergency 
department(s).  
Exploratory: To provide preliminary estimates regarding neurological outcomes following this 
treatment. This study is not adequately sized to provide meaningful comparative data on neurological outcomes. This aim will provide i nsight into the proportion of patients with 
excellent outcomes, along with the proportion of patients with neurologically unsatisfactory 
outcomes.  
 
 
  4.1 DESCRIPTION OF THE STUDY DESIGN   
 
4.2.1  Primary  Endpoints  
 
Co-Primary Endpoint: Time interval from [ADDRESS_648410] 
(qualifying OHCA event) to ED arrival in minutes.  
The primary endpoint was selected because the goal of the study is to demonstrate the 
feasibility of transporti ng patients with refractory OHCA to an ECPR -capable ED within [ADDRESS_648411].  
Co-Primary Endpoint: Time interval from ED arrival to ECPR initiation in minutes  
 
This time interval was chosen because the apparent therapeutic window for OHCA ECPR is 60 minutes and time from ED arrival to ECPR flow is estimated to be 30 minutes.  
 
 
Composite safety endpoint of hemorrhage requiring blood transfusion, pneumothorax 
requiring thoracostomy, hemopericardi um requiring pericardiocentesis.  
Composite safety endpoint of, hemorrhage requiring blood transfusion (greater than 4 units 
packed red blood cells per incident), vessel damage requiring vascular procedure or leading to occlusion, venous/arterial thromboembolism, stroke, renal failure and infection  4 STUDY DESIGN AND  ENDPOINTS  
4.2.2   SAFETY ENDPOINTS  
12   
 
Additional safety outcomes: Splenic injury, liver injury, and all individual components of the 
composite endpoints listed in 4.2.2  
All participants: Utility weighted modified Rankin Scale and cerebral performance category at 
hospi[INVESTIGATOR_5514] 90 days.  
Randomization feasibility: Number of attempted uses of randomization app versus successful 
enrollments  
Patient reported outcomes: Neur o-QOL 
Cognitive functioning outcomes: NIH -Toolbox  
 
 
  5.[ADDRESS_648412] compression devices  and 
Huron Valley Ambulance (HVA) paramedics will be evaluated for this study.  This may include 
ethnic minorities, disabled,  and economically challenged  populations.  
 
 
• Present with out- of-hospi[INVESTIGATOR_164132], presumed non -traumatic etiology, 
requiring  CPR 
• Age presumed or known to be 18 through 70 years old  (prior to 71st birthday)  
• Predicted arrival time at ECPR -capable hospi[INVESTIGATOR_503691]  
• Initial shockable rhythm (ventricular tachycardia or ventricular fibrillation) or 
witnessed pulseless electrical activity or asystole  
• Persistent cardiac arrest after initial cardiac rhythm analysis and shock (if shock is indicated)  
Participants will be enrolled in  the study if they meet initial inclusion criteria at the time of 
their cardiac arrest.  
                                                                                                                                                                                                                                       
4.2.3   EXPLORATORY ENDPOINTS  
5 STUDY ENROLLMENT AND  WITHDRAWAL  
5.1.1 PATIENT LEVEL INCLUSION  
5.1.2 INC LUDED EMS  AGENCIES /  REGIONS /  HOSPI[INVESTIGATOR_281593]  
13   
• Local Fire Department First Responders using mechanical chest compression devices  
including:   
•  Ann Arbor Fire Department First Responders  
• Ann Arbor Township Fire Department First Responders  
• Saline Area Fire Department  
• Scio Township Fire Department First Responders  
• Huron Valley Ambulance  Paramedics  
• Michigan Medicine, University of Michigan  
 
  5.2 PARTICIPANT EXCLUSION  CRITERIA  
Exclusion criteria include:  
• Sustained return of spontaneous circulation (ROSC)  
• DNAR  or DNI advanced  directive  
• Preexisting evidence of opting out of  study  
• Prisoner  
• Pregnant (obvious or  known)  
• ECPR capable ED is not at the destination hospi[INVESTIGATOR_503692]  
• LAR/Family member aware of study and refuses study participation at the  scen e 
 
 
 
There is no participant “recruitment” for this study as it is not possible to prospectively 
identify victims of out -of-hospi[INVESTIGATOR_503693]. 
Participants will be included in the study if they meet enrollment criteria at the time of their 
cardiac arrest. Based on historical data, we anticipate randomizing 30 refractory OHCA patients over 18 months. This clinical trial will be conducted under exception from informed 
consent (further details in Section 13).  
Patients will be screened and assigned a randomization group at the time of dispatch. Study 
eligibility and randomization will be further determined with the aid of an algorithm or expected time to eligible hospi[INVESTIGATOR_503694] a [ADDRESS_648413] met the inclusion criteria (including the refractory nature of the 
cardiac arrest.)  
1. Not eligible continue usual resuscitative care (stay in place until ROSC or resuscitation  
5.3 STRATEGIES  FOR  RECRUITMENT AND  RETENTION  
14  meets termination  criteria)  
2. Eligible,  randomized  to usual  care  (operationally  same  as 1 for paramedics)  
3. Eligible, randomized to early  transport  
 
After an initial rhythm assessment and shock delivery (if indicated), patients who do not have 
ROSC will be considered randomized. Based on the assignment given at the time the  
prehospi [INVESTIGATOR_503695], they will either continue usual care (stay in place until 
ROSC) if assigned to that group (control), or undergo expedited transport with mechanical CPR 
device in place (experimental group). Patients who do not meet inclusion criteria or have 
exclusion criteria will not be considered randomized or enrolled, since no experimental 
procedures will occur to them (standard procedure is for patients to be transported after 
ROSC). If ROSC is achieved during transport or in the emergen cy department (experimental 
group), they will be included in the primary analysis of the expedited transport group. All 
patients will be followed for clinical outcomes.  
All Emergency Medical Services (EMS) personnel (engaged sites) will be trained by a member 
of the study team to the study protocol including randomization, eligibility, study procedures, 
exception from informed consent, and opting -out mechanisms. Training records will be 
maintained with the site coordinator.  
In accordance with the FDA’s Regulations, the investigator must attempt to notify all 
participants that they have been enrolled in a study. If the participant is unable to comprehend this due to loss of consciousness or dies, the investigator must attempt to notify their legally author ized representative.  
Study participants who die in the field or the hospi[INVESTIGATOR_3409], attempts will be made to notify their family/LAR, by [CONTACT_503752][INVESTIGATOR_503696]. Initial contact [CONTACT_503753] a letter requiring a signature/receipt for receipt confirmation. With 
respect for the grieving process, a letter will be sent 2 -4 weeks after the death of the patient. 
These records will also be reviewed and data abstracted, in addition to reviewing for any 
potential adverse events. Letters returned to sender or knowledge initial letter was not 
received, a telephone call will be made, up to 2 times for notification. This will be done by a trained research team member, experienced with discussing sensitive topi[INVESTIGATOR_503697] a loved one.   A communication tracking log will be  kept.  
Study Participants who survive to hospi[INVESTIGATOR_503698]/family member will be approached to notify them of being in the research study and invited to continue study participation, as soon as feasible after hospi[INVESTIGATOR_063]. The person obtaining consent will 
first discuss the study with the participant’s physician or nurse to assess their condition and 
best timing for discussion with them or their LAR/family member. Once signed, a c opy of this 
form is provided to the participant/LAR, in the medical record, and the original will be placed 
[ADDRESS_648414] education and training of engaged agencies and hospi[INVESTIGATOR_503699]. Screening logs will be reviewed regularly with engaged agencies.  
 
  5.4 PARTICIPANT WITHDRAWAL OR  TERMINATION   
 
 
A study participant has the right to withdraw from the study at any time without 
consequence. Reasons for withdrawal may include not wanting to complete the 90 -day 
follow -up visit, becoming tired with the follow -up surveys and requesting to stop, or deciding 
to no longer participate.  
 
 
 
FDA regulations require investigators to prepare and maintain adequate study files recording 
all observations and other pertinent information relative to the clinical trial and when a 
participant or LAR/family member withdrawals further participation, the data already 
collected, remains with the study database.  
If a study participant or LAR/family member declines further study participation, then no further data collection will occur. Since this is an observational study after randomization, 
the participant can safely withdraw and will not be at risk of injury.  
In the case of participant withdrawal, data about their death is contained in public vital 
statistics records and will be queried. Access to public records is not subject to restriction under 21CFR or other FDA regulations.  
 
  5.5 PREMATURE TERMINATION OR SUSPENSION OF STUDY   
 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Written notification, documenting the reason for study suspension or 
termination, will be provided by [CONTACT_91319], 
funding agency, the IND/IDE sponsor and regulatory authorities. If the study is prematurely 
terminated or suspended, the PI [INVESTIGATOR_33894](s) 
for the termination or suspension.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to  participants  
• Demonstration of efficacy that would warrant  stoppi[INVESTIGATOR_007]  
• Insufficient compliance to protocol  requirements  
5.4.1   REASONS FOR WITHDRAWAL OR TERMINATION  
5.4.2   HANDLING OF  PARTICIPANT WITHDRAWALS OR  TERMINATION  
16  • Data that are not sufficiently complete and/or  evaluable  
• Determination of futility  
Study may resume once concerns about safety, protocol compliance, data quality is addressed 
and satisfy the sponsor , IRB and/or FDA.  
 
 
This study is a comparison of two treatment strategies for refractory out -of-hospi[INVESTIGATOR_503700] (OHCA): continued standard care in the field (control) versus expedited transport with ongoing mechanical CPR to a hospi[INVESTIGATOR_503701] (ECPR) in the emergency department (experimental). ECPR is defined as percutaneous veno -arterial extracorporeal membrane oxygenation (ECMO) initiated during 
cardiac arrest. The duration of ECPR is typi[INVESTIGATOR_897] 72 hours to allow the patient’s heart function to recover prior to weaning. Many devices make up an ECMO circuit (cannulas, conduit, 
reservoir, pump, oxygenator, heat exchanger, monitors, sweep gas controller, bubble traps, 
blood filters, positive and negative pressure  monitors and controls). The devices used for 
ECMO are FDA- approved for up to [ADDRESS_648415] is not a FDA approved or cleared indication for ECMO devices, a nd thus is considered investigational in this study. Current 
American Heart Association Guidelines state that “ In settings where it can be rapi[INVESTIGATOR_503702], ECPR may be considered for select cardiac arrest patients for whom the 
suspected etiology of the cardiac arrest is potentially reversible during a limited period of 
mechanical cardiorespi[INVESTIGATOR_1413] (Class IIb, LOE C -LD)”. ECPR is currently performed in the 
University of Michigan University Hospi[INVESTIGATOR_503703]. Examples of local guidelines for EMS and ED care are 
given as appendices B and C.  
 
 
 
  7.1 STUDY  PROCEDURES/EVALUATIONS   
 
7.1.1 Study specific procedures  
Consent  Process  
Participants  or their legally authorized representative (LAR) or family member will be  
approached within a reasonable timeframe and will be requested for consent to continue in the study. The availability and emotional state of LAR/family members will be taken into account, and anticipate a longer timeframe in these situations. The progress of obtaining 
written informed consent will be documented in the medical record. For participants who do not survive to hospi[INVESTIGATOR_063], a letter will be sent as notification.  6 STUDY  INTERVENTION 
7 STUDY  PROCEDURES AND  SCHEDULE  
17  Review of Medical Records  
 
FDA’s regulations require clinical investigators to prepare and maintain adequate and 
accurate case histories (21 CFR 312.62(b) and 812.140(a). In general, the investigator should 
arrange to have access to all records that are generated and maintained from enrollment until 
discharge  or death,  unless  the participant  or their  LAR/family  member  discontinues  the 
participant’s participation in the study. Medical records will be reviewed by a member of the research team u p until this time and if the participant or LAR or family member discontinues 
participation, the data already collected will remain with the study.  
 
Prehospi[INVESTIGATOR_503704]. Run reports become part of the medical record when patients are brought to the emergency department and for cardiac arrests pronounced dead in the 
field, will be sent to the study team securely (i.e. by [CONTACT_6791]).  
The following scales will be performed by a member of the research team at hospi[INVESTIGATOR_503705] 90, in participants who survive.  
Modified Rankin Scale (mRS)  
 
 
The mRS is commonly used for measuring the degree of disability or dependence in the daily 
activities of people who have suffered a neurological disability. mRS score is widely used in stroke research.  
Cerebral Performance Categories Scale (CPC)  
 
CPC score is widely used in cardiac arrest research to assess neurologic outcome. 
NIH Toolbox  
The NIH toolbox includes several cognitive, motor, and psychological tests. It can be  
administered via an iPad.  
 
 
 
 
Standard care for the treatment of OHCA will include cardiac defibrillators, mechanical CPR, 
intravenous (IV) therapy, arterial blood pressure monitoring, central line monitoring, intubation, mechanical ventilation, heart monitoring, cardiac catheterization, hypothermic  
7.1.[ADDRESS_648416] procedures for 
engaged prehospi[INVESTIGATOR_378012]/agencies and qualified emergency departments will be followed. Examples of prehospi[INVESTIGATOR_503706] -hospi[INVESTIGATOR_503707] B and C.  
 
 
 
No biological materials, including blood samples, will be obtained as part of this study  
protocol.  
 
 
Screening  (Day 0, Field Baseline)  
 
Screening will be done by [CONTACT_439064][INVESTIGATOR_503708] -of-hospi[INVESTIGATOR_503709]. All out -of-hospi[INVESTIGATOR_503710], meeting inclusion criteria will be 
considered for the study.  
 
 
Pre Enrollment – Treatment Group Assignment / Randomization  
 
At the time of dispatch of EMS, the dispatcher will enter the address of the arrest, age of the 
patient, and time of 911 call into a web form. The form will use an application to determine 
whether the patient is within the travel distance to arrive at the hospi[INVESTIGATOR_503711] - 
specified interval.  They will immediately receive one of the following messages:  
1) Not eligible, continue usual resuscitative care (patient may be out of geographic  time 
area, may be over 71 years  old) 
2) Eligible, randomized to usual care  
3) Eligible, randomized to early  transport.  
If the dispatcher is unable to access the assignment/randomization website, there will be a study team member, with access rights to the website available by [CONTACT_141224].  
 
 
Pre-hospi[INVESTIGATOR_503712](s) will be reviewed for study eligibility and enrollment criteria. The 
emergency department and hospi[INVESTIGATOR_503713], including time intervals from 911 call to randomiz ation and 911 call to  
7.2.1   CLINICAL  LABORATORY EVALUATI ONS  
7.2 LABORATORY  PROCEDURES/EVALUATIONS  
7.3.1   SCREENING  
7.3 STUDY  SCHEDULE  
7.3.2   ENROLLMENT/BASELINE  
19  emergency department admission, if applicable. Until hospi[INVESTIGATOR_2345], all data collected 
will come from previously collected medical records.  
Initial Enrollment/Field Baseline  (Day 0)  
 
Patients will be enrolled and randomized if they meet the inclusion criteria, namely, the 
presence of refractory cardiac arrest (defined as no ROSC after initial rhythm analysis and 
shock if indicated). The treatment group was pre -assigned during the screening phase, but 
patients with i mmediate ROSC are considered screened out of the study as no experimental 
intervention will occur to them.  
Patients with persistent cardiac arrest in the field who are randomized will be followed for clinical outcomes per the protocol whether or not they h ave ECPR.  
Due to the sudden and urgent nature of cardiac arrest, treatment must occur immediately. 
Enrollment  will occur  at the time  of randomization  by [CONTACT_355077][INVESTIGATOR_503714]- of-hospi[INVESTIGATOR_503715].  Patients will be enrolled  under the  exception  from  
informed consent (EFIC)  process.  
 Prehospi[INVESTIGATOR_503716] (BLS) and Advanced Life Support (ALS) 
document the events of the [ADDRESS_648417] and for participants who dies prior to the emergency department will be collected directly from the agencies.  
 
EMS medical records will be reviewed and the following data abstracted:  
• Date and time of 911  call 
• Time of index cardiac  arrest  
• Status of witnessed arrest  
• Status of By[CONTACT_503754] 
• Time of  collapse  
• Time CPR  initiated  
• Duration of EMS  CPR 
• Initial recorded cardiac arrest  rhythm  
• Use of Impedance -threshold  device  
• Use and type of advanced airway  
• Location of cardiac arrest (home, public place, parking lot, street,  etc.)  
• Date and time of ED  arrival 
 
Index Cardiac Arrest/Emergency Department  (Day 0)  
20  Emergency Department (ED) medical records will be reviewed and the following data 
abstracted:  
• Date and time of ED  arrival 
• Status and timing  of  ROSC 
• Demographic  information  
• Physician progress  note(s)  
• Past medical history; known  comorbidities  
• Nurses  notes  
• Tests performed and their  results  
• Procedures performed and their  outcome  
• Status of ECPR  procedure  
o Time of confirmed placement of arterial and venous ECMO  catheters  
o Time of initiation of  ECPR  
• ED Discharge  diagnosis  
• ED disposition  
 
Survival to Hospi[INVESTIGATOR_91595] (Day 0 - Hospi[INVESTIGATOR_449061])  
 
Attempt to notify the participant, LAR, or family member of study participation and seek permission to continue in the study, using the written IRB approved  informed consent form.  
 
Hospi[INVESTIGATOR_503717] d: 
• Date and time of Hospi[INVESTIGATOR_105904]  
• Status of  ROSC 
• Use of therapeutic  hypothermia  
• Neurologic  status  
• Physician progress  note(s)  
• Nurses  notes  
• Tests performed and their  results  
• Procedures performed and their  outcome  
• Assess for serious adverse  events  
 
Hospi[INVESTIGATOR_503718]:  
• Date and time of Hospi[INVESTIGATOR_47850]  
• Survival status  
• Assess for serious adverse  events  
• Discharge  disposition  
 
The following assessments will be performed by a me mber of the study team:  
• CPC 
• mRS  
• NIH Toolbox Cognitive  Testing  
21   Assess for Serious Adverse Events (SAE’s)  
Prehospi[INVESTIGATOR_503719].  
 
 
Follow -up Visit (Day 90 +/ - 15 days)  
The following assessments will be performed by a member of the study team:  
• CPC 
• mRS  
• NIH Toolbox Cognitive  Testing  
• Quality of Life  Survey  
 
 
Final study visit is the Day [ADDRESS_648418]  the ability  to notify  prehospi[INVESTIGATOR_503720]. If a LAR/family member is aware of the study and objects to 
their participation, prehospi[INVESTIGATOR_503721].  
If the participant survives to hospi[INVESTIGATOR_063], a member of the study team will attempt to 
contact [CONTACT_503755]/family member to notify them of study participation and obtain 
informed consent for continued participation in the study. The participant or LAR or family 
member has the right to decline study participation at any time before or after informed 
consent is obtained. A participant, however may not withdraw use of the data already collected.  At the point of termination, the medical record will no longer be reviewed Ho wever, 
data about a participant’s death is contained in public vital statistics records. Access to  public  
records  is not subject to restriction  under  [ADDRESS_648419] (Fiel d 
 Emergen cy 
Depa rtment 
Survival  to Hospi[INVESTIGATOR_503722]/ Day [ADDRESS_648420]  x x x x x x 
Informed Consent Process   x      x      
CPC     x x 
mRS      x x 
NIH Toolbox      x x 
Quality of Life Survey       x 
Monitor Serious Adverse Events  x x x x x x 
ROSC – Return of Spontaneous Circulation 
CPC – Cerebral Performance Category 
mRS – Modified Rankin Scale  
 
 
  7.[ADDRESS_648421] patients will experience one  or more SAEs as part of routine clinical care.  
 
 
An adverse event (AE) is any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding), symptom, or disease temporally as sociated with the use of a 
medical treatment or procedure regardless of whether it is considered related to the medical 
treatment or procedure (attribution of unrelated, unlikely, possible, probable, or definite).  
Each AE is a unique representation of a specific event used for medical documentation and 
scientific analysis.  
 
 
A serious adverse event (SAE) is an AE that is fatal or life threatening, is permanently or 
substantially disabling, requires or prolongs hospi[INVESTIGATOR_059], results in a congenital anomaly, requires intervention to prevent permanent impairment or damage, or any event that the 
treating clinician or internal medical monitor judges to be a significant hazard, 
contraindication, side effec t, or precaution. Reporting serious adverse events (SAEs) are 
based on the guidelines of the International Conference on Harmonization (ICH).  
 
 
OHRP considers unanticipated problems involving risks to participants or others to include, in general, any incident, experience, or outcome that meets all of the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol -related  documents, such as the IRB - 
approved research protocol and informed consent document; and (b) the 
characteristics of the participant population being  studied;  
• Related  or possibly  related  to participation  in the research  (“possibly  related”  means 
there is a reasonable possibility that the incident, experience, or outcome may have 
been caused by [CONTACT_3459]);  and 
• Suggests that the research places participants or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was  previously 
known or  recognized.  
This study will use the OHRP definition of UP.  
 
This definition could include an unanticipated adverse device effect, any serious adverse 
effect on health or safety or any life -threatening problem or death caused by, or associated 
with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application, or any other  
8.1.1   DEFINITION OF  ADVERSE EVENTS (AE)  
8.1.2   DEFINITION OF  SERIOUS ADVERSE EVENTS  (SAE)  
8.1.3   DEFINITION OF  UNANTICIPATED PROBLEMS  (UP)  
24  unanticipated serio us problem associated with a device that relates to the rights, safety, or 
welfare of subjects (21 CFR 812.3(s)).  
 
  8.2 CLASSIFICATION OF AN   ADVERSE  EVENT   
 
 
‘Severity’ is not the same as ‘serious.’ Serious is based on patient/event outcome or action  
criteria usually associated with events that pose a threat to a patient’s life or health. The term 
‘severe’ is often used to describe the intensity (severity) of a specific event (as in mild, moderate, severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe headache). Seriousness (not severity) serves as a guide 
for defining regulatory reporting obligations. Most AEs include clinical criteria that describe 
patient/event outcomes or indicated interventions to more clearly substantiate seriousness.  
All adverse events occurring within 24 hours of study enrollment and all serious adverse events occurring during study participation will be documented on the AE case r eport form. 
Adverse events will be documented using the NCI Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE). The CTCAE provides descriptive terminology that will be used for recording and reporting adverse events that occur in the EROCA trial. The CTCAE provides a 
grading (severity) scale for each AE term and AEs are listed alphabetically within categories 
based on anatomy or pathophysiology. The CTCAE (v 3.0) displays Grades 1 -5 with unique 
clinical descriptions of severity for each AE b ased on this general guidance:  
Grade  1: Mild  AE 
Grade  2: Moderate  AE 
Grade  3: Severe AE  
Grade  4: Life- Threatening or  Disabling  AE 
Grade  5: Death related to  AE 
Note: Severity is not equivalent to seriousness. A serious adverse event (SAE) would be any event  in category 4 or 5, and any event in category 3 that required or prolonged 
hospi[INVESTIGATOR_059].  
Not all grades are appropriate for all AEs. Therefore, some AEs are listed with fewer than five options for Grade Selection i.e., Grade 5 (Death) is not appropriate for some AEs and 
therefore is not an option.  A version of the CTCAE is available in the MoP  
 
8.2.1   SEVERITY  OF EVENT  
8.2.2   RELATIONSHIP TO  STUDY AGENT  
25  The site principal investigator [INVESTIGATOR_503723], at the time an AE is reported, 
how likely it is that the AE is caused by [CONTACT_34144]. This determination requires 
clinical judgement, but for purposes of this study an algorithm is used to help the investigator 
provide  reporting  that is as objective  as possible  and consistent  with  reporting  across  the trial.  
Modified for EROCA, based upon: Adverse Events Reporting Requirements SOP. NIH -NIAI D. 
http://www.niaid.nih.gov/ncn/sop/adverseevents.htm , accessed 11 -30-04. 
 
Not related: The temporal relationship between treatment exposure and the adverse event is 
unreasonable or incompatible and/or adverse event is clearly due to extraneous causes (e.g., 
underlying disease, environment)  
Unlikely : May have reasonable or only tenuous temporal relationship to intervention. Must 
meet both of the following conditions:  
• Could readily have been produced by [CONTACT_423]’s clinical state, or  environmental 
or other  interventions.  
• Does not follow known pattern of response to  intervention.  
Possibly :  Must meet any 2 of the 3 following conditions  
 
• Has a reasonable temporal relationship to  intervention.  
• Could not readily have been produced by [CONTACT_423]’s clinical state  or 
environmental or other interventions.  
• Follows a known pattern of response to  intervention.  
Probably :  Must meet all 3 of the following conditions  
 
• Has a reasonable temporal relationship to  intervention.  
• Could not readily have been produced by [CONTACT_423]’ s clinical state or have  been 
due to environmental or other  interventions.  
• Follows a known pattern of response to  intervention.  
Definitely :  Must meet all 3 of the following conditions  
 
• Has a reasonable temporal relationship to  intervention.  
• Could  not poss ibly have  been  produced by [CONTACT_423]’s  clinical state  or have  been 
due to environmental or other  interventions.  
• Follows a known pattern of response to  intervention.  
26   
 
The site principal investigator [INVESTIGATOR_503724]. An AE will be considered unexpected if the nature, severity, or frequency of 
the event is not consistent with the risk information previously described for the study agent.  
 
  8.3 TIME PE RIOD AND FREQUENCY FOR EVENT ASSESSMENT  AND  FOLLOW -UP  
 
The occurrence of an AE or SAE may come to the attention of study personnel during study 
visits and interviews of a study participant presenting for medical care, or upon review by a 
study monitor. All AEs including local and systemic reactions not meeting the criteria for SAEs 
will be captured on the appropriate RF. Information to be collected includes event description, time of onset, clinician’s assessment of severity, relationship to study produc t (assessed only 
by [CONTACT_8703] a diagnosis), and time of 
resolution/stabilization of the event. All AEs occurring while on study must be documented 
appropriately regardless of relationship. All AEs will be followed to ade quate resolution.  
Any medical condition that is present at the time that the participant is screened will be 
considered as baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE. UPs will be 
recorded in the data collection system throughout the study.  
Changes in the severity of an AE will be documented to allow an assessment of the duration of 
the event at each level of severity to be performed. AEs characteri zed as intermittent require 
documentation of onset and duration of each epi[INVESTIGATOR_1865].  
The PI [INVESTIGATOR_503725] 24  hours ( for non -serious AEs) or [ADDRESS_648422] day of 
study participation  (for SAE’s) . At each study visit, the investigator  or study coordinator  will 
inquire about the occurrence of SAEs since the last visit. Events will be followed for outcome information until resolution or stabilization.  
 
  8.4 REPORTING  PROCEDURES   
 
An adverse event (AE) is any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure regardless of whether it is considered related to the medical 
treatment or procedure (attribution of unrelated, unlikely, possible, probable, or definite).  
Each AE is a unique representation of a specific event used for medical documentation and 
scientific  analysis.  
8.2.3   EXPECTEDNESS  
27  A serious adverse event (SAE) is an AE that is fatal or life threatening, is permanently or 
substantially disabling, requires or prolongs hospi[INVESTIGATOR_059], results in a congenital anomaly, requires intervention to prevent permanent impairment or damage, or any event that the 
treating clinician or internal medical monitor judges to be a significant hazard, contraindication, side effect, or precaution. Reporting serious adverse events (SAEs) are 
based on the guidelines of the Internati onal Conference on Harmonization (ICH).  
 
 
 
All AEs occurring within 24 hours of study participation and all serious adverse events (SAEs) 
occurring  up until  [ADDRESS_648423] day of study  participation are recorded on the online AE case 
report form (CRF) through the study database. The Site PI [INVESTIGATOR_503726]/she 
becomes aware of the event  and updating the information (e.g., date of resolution, action 
taken) in a timely manner. All non -serious AEs must be recorded on the electronic AE CRF 
within 5 days from the time it was discovered by [CONTACT_145881]. (All non- serious AEs 
during hospi[INVESTIGATOR_503727] [ADDRESS_648424].) For SAEs, the data entry must take place within 24 hours of discovery of the event.  
The Site PI [INVESTIGATOR_503728] -up of AEs until resolution (or end of 
study for that subject) and appropriate documentation in the subject research record. In 
addition to performing protocol -specified follow up, the participating PI [INVESTIGATOR_503729]. If an AE that was previously 
reported on the Adverse Event CRF fully resolves and then recurs at a later date, the second occurrence is considered a new AE and a new Adverse Event CRF must be completed.  
Likewise, if an SAE that was previously reported and subsequently fully resolved later recurs at 
a level requiring expedited reporting, the SAE must be reported as a new SAE on the Adverse 
Event CRF.  
Upon completion of the study protocol by [CONTACT_423], premature withdrawal from the study 
by [CONTACT_423],  or subject’s death, all information regarding each AE must be completed, if not 
done so earlier.  
 
 
The study clinician will complete a SAE Form within the following timelines:  
 
All Serious Adverse Events (SAEs) occurring during a subject’s study participation will be recorded  up until [ADDRESS_648425] as FDA  requests.  
 
 
 
Incidents or events that meet the OHRP criteria for UPs require the creation and completion 
of an  UP report  form.  It is the site investigator’s  responsibility  to report  UPs to their  IRB and to 
the DCC/study sponsor. The UP report will include the following  information:  
• Protocol identifying information: protocol title and number, PI’s name, and the IRB 
project  number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience,  or 
outcome represents an  UP; 
• A description  of any changes  to the protocol  or other  corrective  actions  that have  been 
taken or are proposed in response  to the  UP. 
To satisfy the requirement for prompt reporting, UPs will be reported using the following 
timeline:  
UPs that are SAEs will be reported to the IRB and to the DCC/study sponsor within 7 days of 
the investigator becoming aware of the event.  
Any ot her UP will be reported to the IRB and to the DCC/study sponsor within 7 days of the 
investigator becoming aware of the problem.  
All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s 
written reporting procedures ), the supporting agency head (or designee), and OHRP within 7 
days of the IR ’s receipt of the report of the problem from the investigator.  
An investigator shall submit to the sponsor and to the reviewing IRB a report of any 
unanticipated adverse device effect occurring during an investigation as soon as possible, but in no event later than [ADDRESS_648426] (21 CFR 812.150(a)(1)), A sponsor who conducts an evaluation of an unanticipated adverse device  
8.4.[ADDRESS_648427] under 812.46(b) shall report the results of such evaluation to FDA and to all reviewing 
IRB's and participating investigators within [ADDRESS_648428] as FDA requests (21 CFR 812.150(b)(1)).  
 
 
Not applicable  
 
 
Patients who are obviously pregnant will not be enrolled. If pregnancy  is discovered, the team 
will request permission to follow pregnant women to pregnancy outcome. As the intervention 
(early transport with mechanical CPR) occurs prior to laboratory testing, no additional treatment is possible under this protocol after the discovery of pregnancy and patients are 
only on the protocol for the collection of outcomes.  
 
  8.[ADDRESS_648429] semiannually to assess safety and efficacy data on each arm of the study. The DMSB will 
operate under the rules of an approved charter that will be written and reviewed at the 
organizational meeting of the DSMB. At this time, each data element that the DSMB needs to assess will be clearly defined. The DSMB will provide its input to NIH. We will provide tables 
providing all SAEs by [CONTACT_19313], along with clinical outcomes, and a listing of SAEs by [CONTACT_503756] (given the small sample size of EROCA), as part of reporting to DSMB.  
 
 
Clinical site monitoring is conducted to ensure that the rights and well -being of human 
subjects are protected, that the reported trial data are accurate, complete, and verifiable, and 
that the conduct of the trial is in compliance with the currently approved 
protocol/amendment(s), with GCP, and with applicable regulatory requirement(s).  
• Designated study staff not involved with the enrollment will conduct monitoring.  This 
will occur throughout the study, and will involve targeted or review of certain data (primary  
8.4.[ADDRESS_648430]  
8.4.5   REPORTING  OF PREGNANCY  
9 CLINICAL  MONITORING  
30  endpoints, safety endpoints, consent forms). Monitoring reports will be distributed to the  PI 
[INVESTIGATOR_503730].  
• Independent audits will not be  conducted.  
 
• Each clinical site will perform internal quality management of study conduct, data 
collection, documentation and completion. As necessary, individualized quality  management 
plans will be developed to describe a site’s quality  management.  
 
 
  10.1  STATISTICAL  AND  ANALYTICAL  PLANS   
 
This is a pi[INVESTIGATOR_4251], designed to demonstrate proof of feasibility prior to a larger scale trial that 
will be powered  to improve patient outcomes. The primary endpoints target process 
measures, namely the delivery of randomized patients to the qualified ED within 30 minutes of qualifying event.  
 
  10.2  STATISTICAL HYPOT HESES   
• Co-Primary Endpoint(s): Arrival to qualified  ED within 30  minutes  
 
We hypothesize that the proportion of patients randomized to early transport arriving at the 
hospi[INVESTIGATOR_79638] 30 minutes will be greater than the historical proportion of 38.7%.  
• Co-Primary Endpoint(s): Initiation of ECPR within 30 minutes of ED arrival  
 
We hypothesize that greater than or equal to 80% of patients will have ECPR (qualifying ED 
standard care process) initiated within [ADDRESS_648431] ROSC after initial rhythm analysis (and shock if indicated) 
and have the early transport initiated will be considered the primary analytic population for 
the ED arrival endpoint. Patients who are randomized to early transport and remain in cardiac 
arrest for at least [ADDRESS_648432] care ECPR 
process initiated are considered the primary analytic population for the ECPR initia tion 
endpoint. Exploratory clinical and safety endpoints will be collected on the entire population 
of refractory OHCA patients enrolled/randomized to either early transport or usual care.  
 
  10.4  DESCRIPTION  OF  STATISTICAL  METHODS   10 STATISTICAL  CONSIDERATIONS  
31   
 
The primary goal of this study is to establish that a high proportion of patients with refractory 
OHCA can be expeditiously transported to the hospi[INVESTIGATOR_503731]. 
Randomization is not intended to create comparable groups, but instead is being used to 
demonstrate the feasibility of using a position sensitive randomization procedure in the field. 
Randomization in this protocol includes two currently used approaches to OHCA: expedited 
transport to the  hospi[INVESTIGATOR_503732].  
Descriptive statistics for study groups will be presented as medians, and interquartile ranges 
for continuous data; categorical data will be r eported as proportions.  
Patients randomized to the test arm and achieve ROSC prior to initiation of ECPR will be included in the 
primary analysis of the expedited transport group.  
 
 
Co-Primary Endpoint(s): Arrival to qualified ED within 30 minutes  
 
The proportion of qualifying epi[INVESTIGATOR_503733] 30 minutes will be compared 
to our historical data point estimate of 38.7% using a one sample exact test of binomial 
proportions at the 0.05 two -sided significance level.  
Co-Primary Endpoint(s): Initiation of ECPR within [ADDRESS_648433] in the qualified ED, we will declare the analysis of this objective succe ssful if 80% or more of patients have 
ECPR (qualifying ED standard care process) initiated within [ADDRESS_648434] any powered secondary endpoints. All clinical and other process 
endpoints are exploratory.  
 
 
This is a small clinical trial. We will summarize SAEs by [CONTACT_2060] (early transport versus 
usual care) and provide a listing of all SAEs f or each of the patients in the intent to treat 
population.  
 
10.4.1 GENERAL APPROACH  
10.4.2 ANALYSIS OF  THE  PRIMARY EFFICACY ENDPOINT(S)  
10.4.3 ANALYSIS OF THE  SECONDARY ENDPOINT( S)  
10.4.4 SAFETY ANALYSES  
10.4.5 ADHERENCE AND RETENTION  ANALYSES  
32  We will qualitatively summarize the reasons that patients were randomized but that the 
assigned early transport or usual care pathways were not followed. We will qualitatively 
summarize reasons for participant withdrawal.  
 
 
We will provide descriptive statistics including demographic variables by [CONTACT_2060] (early 
transport  versus usual care). As the patients are randomized in the field, no baseline 
laboratory variables are available. No hypothesis testing will be used to compare the groups 
due to the small sample size.  
 
 
 
 
The DSMB will review safety data as per their charter. The main listed safety endpoints will be 
reviewed. No formal statistical boundaries will be used to determine stoppi[INVESTIGATOR_503734].  
 
 
We will not employ formal stoppi[INVESTIGATOR_503735] -specify subgroup analyses of the primary endpoints by [CONTACT_547], age (less than 50 
versus 51 -70), diabetes, p rior cardiac disease, and race/ethnicity. These subgroup analyses 
will be presented graphically and in tables. Given the small sample size formal hypothesis testing will not be performed. In addition, we will also categorize the defined safety endpoints 
by [CONTACT_503757], graphically and in  tables.  
 
 
We are employing two primary endpoints, but no adjustment for multiplicity will be 
performed as the process endpoint is a threshold.  
 
 
Individual participant data for the primary endpoints will be summarized in tabular form. We 
will also include exploratory endpoint data (mRS and CPC) in these tables.  
10.4.6  
 BASELINE  DESCRIPTIVE STATISTICS  
10.4.7 PLANNED  INTERIM ANALYSES  
[IP_ADDRESS]  
 SAFETY REVIEW  
[IP_ADDRESS]  
 EFFICACY REVIEW  
10.4.8 ADDITIONAL  SUB -GROUP ANALYSES  
10.4.9 MULTIPLE COMPARISON/MULTIPLICITY  
10.4.10  
 TABULATION  OF  INDIVIDUAL RESPONSE DATA  
33   
 
Each of the exploratory endpoints will be summarized using appropriate techniques based on 
the distribution (for continuous variables) or event rates (for categorical variables). Group (early transport versus usual care) comparisons will be presented in graphical, or tabular form for the exploratory endpoints. Formal hypothesis testing will be avoided given the small 
sample size.  
 
  10.[ADDRESS_648435] 24 (80%) of these. 
With 24 patients, if we find that 19/24 (79.2%) of cases meet time limit we have 98% power to 
find that the proportion of patients arriving at the ED within 30 minutes is significantly different than in 2014. The protocol will be deemed optimal if ≥19/24 patients are transported 
to the ED within 30 minutes (95% CI lower bound 62.6%).  
 
  10.[ADDRESS_648436] the next treatment assignment, and as such, the risk 
of bias is low.  
Randomization will occur in blocks of 5. We will use an urn method. Randomization will not be stratified by [CONTACT_503758][INVESTIGATOR_503736]. The blocking is intended to maintain balance. The randomization ratio is 4:1 with the expedited transport group 
favored. Since the main study goals involve the expedited transport of patients to the hospi[INVESTIGATOR_503737] 4:1 ratio is justified. In addition, expedited versus 
delayed transport are both currently used treatment strategies for OHCA across North 
America and there is equipoise about assignment into either of these groups.  In situations 
where the dispatcher uses the website and gives a treatment group assignment, but the patient is not enrolled/randomized in the study because they did not have refractory cardiac arrest, that treatment group assignment will be returned to the urn.  
 
 
This study is unblinded.  
10.4.11  
 EXPLORATORY ANALYSES  
10.6.1 ENROLLMENT/ RANDOMIZATION/ MASKING  PROCEDURES  
10.6.2 EVALUATION OF  SUCCESS OF BLINDING  
34   
 
The entire study will be conducted using an electronic data acquisition method where all 
clinical data on enrolled subjects will be data entered (single -keyed) by [CONTACT_449038] 
a web -based data management system. In order to provide user -friendly and easy -to-navigate 
interfaces, the data capture screens are designed based upon individual CRFs . Prior to study 
start, the system is validated to ensure the data entry screens mirror the CRFs and that the pre-programmed data rules appropriately detect incorrect data. The data will be managed 
after data entry via data queries from the Coordinating Ce nter at UM.  
The latest version of each CRF will be available for use as worksheets and source documents by [CONTACT_3462]. This process facilitates version control of these study related documents, 
particularly since documents may evolve over the course o f the study. This user friendly web- 
based database system, developed by [CONTACT_434], will be used for data entry, 
data validation, project progress monitoring, subject tracking, tracking, user customizable 
report generation and secure data tra nsfer.  
 
 
QC procedures will be implemented beginning with the data entry system and data QC checks 
that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.  
Following written SOPs, the monitors will verify that the clinical trial is conducted and data are 
generated, documented (recorded), and reported in compliance with the protocol, GCP, and 
the applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good 
Manufacturing Practices (GMP)).  
The investigational site will provide direct access to all trial related sites, source 
data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], and 
inspection by [CONTACT_3482].  
 
 
 
 
 
The investigator will ensure that this study is conducted in full  conformity with Regulations 
for the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 
21 CFR Part 56, and/or the ICH E6. Additional details regarding EFIC are provided in appendix 
A . Below when referring to the participant or individual, it is highly likely that the legally  11 SOURCE  DOCUMENTS AND ACCESS TO  SOURCE  DATA/DOCUMENTS  
12 QUALITY ASSURANCE AND QUALITY  CONTROL  
13 ETHICS/PROTECTION  OF  HUMAN  SUBJECTS  
13.[ADDRESS_648437] will be providing consent as the patients will likely 
remain comatose in the early emergency department care.  
1. Subjects are in a life -threatening situation, available treatments are unproven or 
unsatisfactory, and the collection of valid scientific evidence is necessary to  determine 
the safety and effectiveness of a particular  intervention.  
 
a. Cardio -pulmonary resuscitation (CPR) is the first line of treatment for a  cardiac 
arrest, a life -threatening situation, and must be initiated immediately. This 
study will enroll patients not responding to standard basic life support (BLS) and advanced cardiovascular life support (ACLS) and no other alternative treatments are proven effective when the arrest is refractory to standard 
therapy.  
b. The vast majority of people who suffer an out of hospi[INVESTIGATOR_164132]  (OHCA) 
die, despi[INVESTIGATOR_503738] -trained emergency medical service (EMS) 
providers.  It is  unknown whether standard CPR can be  improved.  
c. Based on the CARES registry data for Washtenaw/Livingston Medical Control Authority (MCA), 408 OHCA patients were treated in 2014, 133 (33%)  achieved 
sustained return of spontaneous circulation and only 30 sur vived to hospi[INVESTIGATOR_7954] (7.4%) with only 24 (5.9%) having good neurologic function at hospi[INVESTIGATOR_2345]. This is well below the national survival rate of  8-10%.  
d. Clinical trials are needed. No prospective, randomized clinical trial has compared standard CPR to ECPR. Almost all published case series of successful 
ECPR from OHCA initiate ECPR in the emergency department [Chen 2008, 
Kagawa 2010, Nagao 2000 and 2010, LeGuen 2011, Morimura 2011, Avali 2012, Bellezzo 2012, Johnson 2014, Sakamoto 2014, Stub 2014]. The reason for this 
strategy is that the shorter the interval from cardiac arrest onset to initiation of 
ECPR is. The better the chance for a favorable outcome. Scientific evaluation is 
necessary in order to further test the efficacy of the proposed i ntervention, 
transport to an ED for higher level of care and  ECPR.  
2. Obtaining informed consent is not feasible  because:  
 
a. Patients who are in cardiac arrest are unresponsive and unable to 
communicate. It is unreasonable and impractical for first responders t o 
identify, verify, and obtain consent from a legally authorized  representative.  
b. The optimal therapeutic window for initiating interventions and ECPR is  within 
[ADDRESS_648438] benefit to the  subjects 
because:  
 
a. Patients are in a life -threatening  situation  
 
b. Published case series where initiating ECPR in the emergency department  have 
reported survival rates with  good neurologic function ranging from  4-33%  
c. Potential risk of complications of transport with mechanical CPR (rib fractures, 
pneumothorax, internal organ laceration or motor vehicle crash) or ED  initiated 
ECPR (hemorrhage, vascular injury, deep venous thrombosis, pulmonary 
embolism, stroke, lime ischemia, infection) are balanced by [CONTACT_503759].  
4. The clinical investigation could not be practicably be carried out without the  waiver  
 
a. Time to treatment for c ardiac arrest needs to begin immediately. Since these 
patients are unable to consent for themselves and there is not time to identify, 
inform, and consent a legally authorized representative, all patients must be 
enrolled under EFIC. Additionally, informed  consent requires the LAR to have 
time to understand the consent material, be able to ask questions, and 
decipher what the patient would want. This is not possible to do in a few 
minutes and during such a stressful time. Inability to obtain informed consent can limit the ability to discover new treatments for such a critical and life - 
threatening event like sudden cardiac  arrest.  
5. Length of the potential therapeutic window and contact a legally  authorized 
representative.  
 
a. The optimal therapeutic window is immediate or non -existent. Randomization 
into the study must be done immediately, at the time of initiating  CPR.  
Every effort will be made to identify, inform, and determine consent to continue in the study 
from a legally authorized representative, in a reasonable amount of time.  
Participants who regain good neurologic function and are able, will be informed and consent 
will be attempted.  
 
  13.[ADDRESS_648439]   
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the IRB for review and approval. Approval of both the protocol and the  
[ADDRESS_648440] be obtained before any participant is enrolled. Any amendment to the 
protocol will require review and approval by [CONTACT_214480]. All changes to the consent form will be IRB approved; a determination will be made 
regarding whether previously consented participants need to be re -consented.  
 
 
Initial enrollment is initiated under and exception from informed consent as the patient is 
unconscious in cardiac arrest. Enrollments will not occur until after EFIC plan and protocol approval by [CONTACT_56335](s).  
Consent forms describing in detail the study agent, study procedures, and risks are given to the participant and written documentation of informed consent is required prior to continuing study procedures. The f ollowing consent materials are submitted with this protocol: informed 
consent to continue participation, notification letters.  
 
 
Informed consent is a process that is initiated prior to the participant or the  individual’s legally 
authorized representative agreeing to continue to participate in the study and continues  
throughout the individual’s study participation. Extensive discussion of risks and possible benefits of continued participation will be provided to the participants and their families  along 
with a description of what has occurred so far given initial enrollment under EFIC. Consent forms will be IRB -approved and the participant will be asked to read and review the 
document. The investigator will explain the research study to the participant and answer any 
questions that may arise. All participants will receive a verbal explanation in terms suited to 
their comprehension of the purposes, procedures, and potential risks of the study and of their 
rights as research participants. Participants will have the opportunity to carefully review the 
written consent form and ask questions prior to signing. The participants should have the 
opportunity to discuss the study with their surrogates or think about it prio r to agreeing to 
participate. The participant will sign the informed consent document prior to any procedures being done specifically for the study. The participants may withdraw consent at any time throughout the course of the trial. A copy of the informed consent document will be given to 
the participants for their records. The rights and welfare of the participants will be protected 
by [CONTACT_503760].  
 
  13.4  PARTICIPANT  AND  DATA CONFIDENTIALITY   
13.3.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS  
13.[ADDRESS_648441] by [CONTACT_3486], their staff, 
and the sponsor(s) and their agents. This confidentiality is extended to cover testing of 
biological samples and genetic tests in addition to the clinical information relating to 
participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data 
will be released to any unauthorized third party without prior written approval of the sponsor.  
The study monitor, other authorized representatives of the sponsor or representatives of the 
IRB may inspect all do cuments and records required to be maintained by [CONTACT_093], 
including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
The study participant’s contact [CONTACT_65246]. At the end of the study, all records will continue to be kept in a 
secure location for as long a period as dictated by [CONTACT_46202].  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the Coordinating Center at University of 
Michigan. This will not include the pa rticipant’s contact [CONTACT_1290]. Rather, 
individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by [CONTACT_503761]. At  
the end of the study, all study databases will be de -identified and archived at the Coordinating 
Center.  
 
  
 
 
 
Intended Use: Samples and data collected under this protocol may be used to study cardiac 
arrest. No genetic testing will be performed.  
Storage: Samples and data will be stored using codes assigned by [CONTACT_473]. Data will 
be kept in password- protected compu ters. Only investigators will have access to the samples 
and data.  
 
  13.5  FUTURE USE  OF  STORED  SPECIMENS   
 
Data collected for this study will be analyzed and stored at the Coordinating Center (UM). 
After the study is completed, the de -identified, archived data will be transmitted to and 
stored at the institutional or NHLBI determined data repository, under the supervision of UM  
13.4.1 RESEARCH USE  OF  STORED HUMAN SAMPLES,SPECIMENS OR  DATA  
39  and/or NHLBI, for use by [CONTACT_21227]. Permission to 
transmit data  to the UM institutional data repository will be included in the informed consent.  
When the study is completed, access to study data and/or samples will be provided through 
the UM institutional data repository.  
 
 
[ADDRESS_648442]  KEEPI[INVESTIGATOR_1645]  
14.1  DATA  COLLECTION  AND  MANAGEMENT  RESPONSIBILITIES  
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site PI. The investigator is responsible for ensuring the accuracy, completeness, legibility, 
and timeliness of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data. Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When 
making changes or corrections, cross out the original entry with a single line, and initial and 
date the change. DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
Copi[INVESTIGATOR_58625] (eCRF ) will be provided for use as source documents and 
maintained for recording data for each participant enrolled in the study. Data reported in the 
eCRF derived from source documents should be consistent with the source documents or the 
discrepancies should be explained and captured in a progress note and maintained in the 
participant’s official electronic study record.  
Clinical data (including AEs) and expected adverse reactions data) and clinical laboratory data 
will be entered  into,  a [ADDRESS_648443]. These documents 
should be retained for a longer period, however, if required by [CONTACT_427].  No records 
will be destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no longer need to be retained.  
40    14.3  PROTOCOL  DEVIATIONS   
 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or MOP 
requirements. The noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions are to  be 
developed by [CONTACT_3483].  
These practices are consistent with ICH E6:  
 
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and  4.5.3  
 
• 5.1 Quality Assurance and Quality Control, section  5.1.1  
 
• 5.[ADDRESS_648444] be sent to the local IRB per 
their guidelines. The site PI/study staff is responsible for knowing and adhering to their IRB requirements. Further details about the handling of protocol deviations will be included in the MOP. 
 
  14.4  PUB LICATION  AND  DATA SHARING  POLICY   
 
This study will comply with the NIH Public Access Policy, which ensures that the public has access to the published results of NIH funded research. It requires scientists to submit final 
peer -reviewed  journal  manuscripts  that arise  from  NIH funds  to the digital archive  PubMed 
Central upon acceptance for  publication.  
The International Committee of Medical Journal Editors (ICMJE) member journals have 
adopted a clinical trials registration policy as a condition fo r publication. The ICMJE defines a 
clinical trial as any research project that prospectively assigns human subjects to intervention 
or concurrent comparison or control groups to study the cause -and-effect relationship 
between a medical intervention and a health outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process -of-care changes, and the like.  
Health outcomes include any biomedical or health -related measures obtained in patients or 
participants, including pharmacokinetic measures and adverse events. The ICMJE policy, and 
the Section [ADDRESS_648445] of 2007, requires that all clinical trials be registered in a public trials registry such as clinicaltrials.gov , which is 
sponsored by [CONTACT_1055]. Other biomedical journals are considering 
adopting similar policies. For interventional clinical trials performed under NIH IC grants and 
cooperative agreements, it is the grantee’s responsibility to regist er the trial in an acceptable  
41  registry, so the research results may be considered for publication in ICMJE member journals. 
The ICMJE does not review specific studies to determine whether registration is necessary; instead, the committee  
recommends that researchers who have questions about the need to register err on the side of registration or consult the editorial office of the journal in which they wish to publish.  
FDAAA mandates that a "responsible party" (i.e., the sponsor o r designated principal 
investigator) register and report results of certain "applicable clinical trials":  
• Trials of Drugs and Biologics: Controlled, clinical investigations, other than Phase 
I investigations, of a product subject to FDA  regulation;  
• Trials of Devices: Controlled trials with health outcomes of a product subject to FDA 
regulation (other than small feasibility studies) and pediatric postmarket surveillance  
studies.  
NIH grantees must take specific steps to ensure compliance with NIH implementati on of 
FDAAA  
 
 
  15.[ADDRESS_648446] patients treated with extracorporeal membrane oxygenation: an 
Italian tertiary care centre experience. Resuscitation. 2012:83:579 -83. PMID: 22056265  
Bartlett RH, Roloff DW, Cornell RG, Andrews AF, Dillon PW, Zwischenberger JB. 
Extracorporeal circulation in neonatal respi[INVESTIGATOR_1399]: a prospective randomized study. Pediatrics. 1985;76:479- 487. PMID: 3900904  
Bartlett RH, Roloff DW, Custer JR, Younger JG, Hirschl RB. Extracorporeal life support: the University of Michigan e xperience. JAMA. 2000;283:904- 8. PMID: 10685715  
Bartlett RH. Clinical Research in Acute Fatal Illness: Lessons From Extracorporeal Membrane Oxygenation. J Intensive Care Med. 2014 Sep 15. [Epub ahead of print] PMID: 25223826  
Bellezzo JM, Shinar Z, Davis DP , et al. Emergency physician -initiated extracorporeal 
cardiopulmonary resuscitation. Resuscitation 2012;83:966 –70.26. PMID: [ADDRESS_648447] -resuscitation care. Resuscitation. 2014;85:915 - 
9. Epub 2014 Apr 13.PMID: [ADDRESS_648448] CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino  MW, Drajer S, 
Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation.  
201520;132([ADDRESS_648449] 1):S84- S145. PMID: [ADDRESS_648450]: an observational study and propensity analysis. Lancet 2008;372:554 –61. 
PMID: 18603291  
Chaisinanunkul N, Adeoye O, Lewis RJ, Grotta JC, Broderick J, Jovin TG,  Nogueira RG, Elm JJ, 
Graves T, Berry S, Lees KR, Barreto AD, Saver JL. Adopting a Patient -Centered Approach to 
Primary Outcome Analysis of Acute Stroke Trials Using a Utility -Weighted Modified Rankin 
Scale. Stroke. 2015 ;46:2238- 2243. Epub 2015 Jul 2. PMI D: 26138130  
ELSO Registry accessed 02/08/2015. https://www.elso.org/Registry/Statistics.aspx  
ELSO Website: Protocols accessed 02/15/2015 https://www.elso.org/Portals/0/IGD/Archive/FileManager/6713186745cusersshyerdocument  
selsoguidelinesforecprcases1.3.pdf  
Fagnoul D, Taccone FS, Belhaj A, Rondelet B, Argacha JF, Vincent JL, Backer DD. Extracorporeal life support associated with hypothermia and normoxemia in refractory 
[ADDRESS_648451]. Resuscitation. 2013;84:1519- 24. PMID: 23816899  
Fagnoul D, Combes A, De Backer D. Extracorporeal cardiopulmonary resuscitation. Curr Opin 
Crit Care. 2014;20:259 -65.  PMID: [ADDRESS_648452]. Resuscitation. 2012;83:1331 -7.  PMID: [ADDRESS_648453]. Resuscitation. 2014;85:1527 -32. PMID: [ADDRESS_648454] patients treated with cardiopulmonary resuscitation using 
extracorporeal life support.  Resuscitation. 2010;81:968 -73. PMID: [ADDRESS_648455]?: rapid -response extracorporeal membrane oxygenation and 
intra -arrest percutaneous coronary intervention. Circulation. 20 12;1261605- 13. PMID: 
[ADDRESS_648456]. Resuscitation. 
2013;84:1525- 9. PMID: [ADDRESS_648457]. Crit Care. 
2011;15:R29.  
Link MS, Berkow LC, Kudenchuk PJ, Halperin HR, Hess EP, Moitra VK, Neumar RW, O'Neil BJ, Paxton JH, Silvers SM, White RD, Yannopoulos D, Donnino MW. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Updat e for 
Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132([ADDRESS_648458] 2):S444 -S4464. PMID: [ADDRESS_648459] of cardiac origin: a propensity -matched study 
and predictor analysis. Crit Care Med. 2013;41:1186 -96. PMID: 23388518  
Meurer WJ1, Lewis RJ, Tagle D, Fetters MD, Legocki L, Berry S, Connor J, Durkalski V, Elm J, Zhao W, Frederiksen S, Silbergleit R, Palesch Y, Berry DA, Barsan WG. An overview of the adaptive designs accelerating promising trials into treatments (ADAPT -IT) project. Ann Emerg 
Med. 2012;60:451- 457. PMID: [ADDRESS_648460]: A review of 
the Japanese literature.  Resuscitation. 2011;82:10 -14. PMID: 20934798  
Morrison LJ, LJ Kierzek G, Diekema DS, Sayre MR, Silvers SM, Idris AH, Mancini ME. Part 3: 
ethics: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and 
Emergency Cardiovascular Care. Circulation. 2010;122([ADDRESS_648461] 3):S665 -75. PMID: [ADDRESS_648462], Moy CS, Muntner P, Mussolino ME, Nasi r K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, 
Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart  disease and stroke statistics --2015 update: a report from the American 
Heart Association. Circulation. 2015;131:e29 -322. PMID: [ADDRESS_648463] outside the hospi[INVESTIGATOR_307]. J Am Coll Cardiol 2000;36:776 –83.10. PMID: 
[ADDRESS_648464] who undergo emergency cardiopulmonary by[CONTACT_503762]. Circ J. 2010;74:77 -85. PMID: [ADDRESS_648465], Hess EP, Tang W, Davis D, Sinz E, Morrison LJ. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.  
Circulation. 2010;122([ADDRESS_648466] 3):S729- S767. PMID: [ADDRESS_648467]: the LINC randomized trial. JAMA. 2014;311(1):53 -61. PMID: 
24240611  
Sakamoto T, Morimura N, Nagao K, Asai Y, Yokota H, Nara S, Hase M, Tahara Y, Atsumi T; SAVE -J Study Group. Extracorporeal cardiopulmonary resuscitation versus conventional 
cardiopulmonary  resuscitation in adults with out- of-hospi[INVESTIGATOR_164132]: a prospective 
observational study. Resuscitation. 2014;85:762 -8.  PMID: 24530251  
45  Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, Barsan W; NETT 
Investiga tors. Intramuscular versus intravenous therapy for prehospi[INVESTIGATOR_315522]. N 
Engl J Med. 2012: 16;366:591 -600. PMID: [ADDRESS_648468] 20. [Epub ahead of print]. PMID: 26488218  
Spurlock DJ, Toomasian JM, Romano MA, Cooley E, Bartlett RH, Haft JW. A simple technique to prevent limb ischemia during veno -arterial ECMO using the femoral artery: the posterior 
tibial approach. Perfusion. 2012;27:141 -5. PMID: [ADDRESS_648469] treated with mechanical CPR, hypothermia, ECMO and early reperfusion (the CHEER trial). Resuscitation. 2014 [Epub ahead of print] PMID: [ADDRESS_648470]: seventeen years of experience. Resuscitation. 2013;84(3):326 -30. PMID: 22800860  
46  APPENDICES  
 
  APPENDIX A: Original EFIC  PLAN   
Please see revised Community Consultation and Public Disclosure activities planned for the Saline, 
MI area expansion of the study, provided as a separate document.   
EROCA Trial 
 
Extracorporeal CPR for Refractory Out-of-Hospi[INVESTIGATOR_503739] (EFIC) Plan  
Public  Disclosure  Sites:  Ann Arbor,  MI, Washtenaw County  Plan  Date  Prepared:  May  04, 2016 
Plan Revised  Date  02/02/17  Date of IRB  approval:  9/22/[ADDRESS_648471] be given so rapi[INVESTIGATOR_503740] a surrogate 
decision maker (legally authorized representative). Such trials are therefore performed with 
an exception from informed consent (EFIC) for emergency research, and are governed by a 
special set of research regulations defined at 21 § CFR 50.24. We propose a clinical research 
project, EROCA, to be conducted using EFIC. This document will explain why the project qualifies for EFIC, and how the investigators propose to meet the Community Consultation 
and Public Disclosure requirements for EFIC.  
Research involving OHCA patients presents an ethical dilemma. The resulting delay in obtaining consent can significantly affect the efficacy of an intervention and limits patient 
eligibility for inclusion in such a time -critical study. Despi[INVESTIGATOR_503741], clinical trials to 
determine the best treatment for OHCA must be done. Failing to conduct research on 
potentially beneficial treatment for this population also poses harm.  
Applicability of EFIC to the EROCA Trial and Compliance with FDA Requirement, 21 CFR 
50.24 
Listed below are the FDA regulations that qualify use of the EFIC process in clinical research, 
followed by [CONTACT_503763].  
1. Subjects are in a life -threatening situation, available treatments are unproven or 
unsatisfactory, and the collection of valid scientific e vidence is necessary to  determine 
the safety and effectiveness of a particular  intervention.  
47  a. Cardiopulmonary resuscitation (CPR) is the first line of treatment for a cardiac 
arrest, a life -threatening situation, and must be initiated immediately.  This 
study will enroll patients not responding to standard basic life support (BLS) and 
advanced cardiovascular life support (ACLS) and no other alternative treatments 
are proven effective  when the arrest is refractory to standard  therapy.  
b. The vast majority of people who suffer an out of hospi[INVESTIGATOR_164132]  (OHCA) 
die, despi[INVESTIGATOR_503738] -trained emergency medical service (EMS) 
providers.  It is unknown whether standard CPR can be  improved.  
c. Based on the CARES registry data for Washten aw/Livingston Medical Control 
Authority (MCA), 408 OHCA patients were treated in 2014, 133 (33%) achieved sustained return of spontaneous circulation and only 30 survived to hospi[INVESTIGATOR_7954] (7.4%) with only 24 (5.9%) having good neurologic function at  hospi[INVESTIGATOR_7954]. This is well below the national survival rate of  8-10%.  
d. Clinical trials are needed. No prospective, randomized clinical trial has compared 
standard CPR to ECPR. Almost all published case series of successful ECPR from 
OHCA initiate ECPR in the emergency department [insert references].  The 
reason for this strategy is that the shorter the interval from cardiac arrest onset to initiation of ECPR is. The better the chance for a favorable  outcome.  
Scientific evaluation is necessary in order t o further test the efficacy of the 
proposed intervention, transport to an ED for higher level of care and ECPR.  
 
2. Obtaining informed consent is not feasibe  because:  
a. Patients who are in cardiac arrest are unresponsive and unable to  communicate. 
It is unreasonable and impractical for first responders to identify, verify, and obtain consent from a legally authorized  representative.  
b. The optimal therapeutic window for initiating interventions and ECPR is  within 
[ADDRESS_648472] benefit to the subjects 
because:  
a. Patients are in a life -threatening  situation  
b. Published case series where initiating ECPR in the emergency departmen t have 
reported survival rates with good neurologic function ranging from 4- 33%  
c. Potential risk of complications of transport with mechanical CPR (rib fractures, pneumothorax, internal organ laceration or motor vehicle crash) or ED  initiated 
ECPR (hemorrhag e, vascular injury, deep venous thrombosis, pulmonary 
embolism, stroke, lime ischemia, infection) are balanced by [CONTACT_503764].  
[ADDRESS_648473] udy from a legally authorized representative, in a reasonable 
amount of time.  
Participants who regain good neurologic function and are able, will be informed 
and consent will be attempted.  
 
Additional Protections  
Additional protections of the rights and we lfare of the participants will be provided, 
including:  
1. Community  Consultation  
2. Public Disclosure before the study starts, including opt- out and decline 
participation  options  
3. Public Disclosure following completion of the study; providing  sufficient 
information, including demographic characteristics and study  results.  
4. Establishment of an independent Data Safety Monitoring Board (DSMB)  to 
exercise oversight of the  study.  
5. Plan to contact [CONTACT_84385] (LAR) or family member to seek informed consent for the patient’s participation in the 
study within the therapeutic window if feasible or after enrollment as  soon 
as possible when feasible. If a patient dies prior to hospi[INVESTIGATOR_063], all 
attempts will be made to notify their LAR or family member of the  study  
49  and patient’s participation, if feasible. If a patient regains consciousness 
and is capable, informed consent will be attempted as soon as feasible.  
 
 
The federal requirements of 21 § CFR 50.[ADDRESS_648474] will be done that will involve members of the local population.  
If community consultation were viewed as community consent, this would imply that the input came from a large proportion or essentially all the members of the community as opposed to representatives of the community. The process is meant to solicit input from the community reg arding the study. The IRB makes the final determination as to study approval 
based on information obtained from the community consultation. For the purposes of EFIC, the definition of community includes “the community in which research will take place” and 
the “community from which subjects will be drawn.” In other words the community includes 
the geographical area from which patients will be drawn and the group of patients with, or at risk for, the disease of interest.  
The content of community consultation  will inform the community participants that informed 
consent will not be obtained for any research subjects prior to enrollment. Specifically, the 
goal will be to:  
• Inform the community about relevant aspects of the study including its 
risks and expected b enefits  
• Hear the perspective of the community on the proposed research  
• Provide information about ways in which individuals wishing to  be 
excluded may indicate this  preference  
 
The type and frequency of community consultation will:  
 
• Provide opportunities for broad community  discussion  
• Ensure that representatives from the communities involved in the 
research participate in the consultation  process  
• Use the most appropriate ways to provide for effective  community 
consultation  
• Be based on numerous factors, inc luding the size of the communities, 
the languages spoken within those communities, the targeted research 
population and the heterogeneity of the  population Community Consultation  
[ADDRESS_648475].  
  
 
The consultation will encompass the following three major forms:  
 
1. Visits to existing community groups at regularly scheduled meetings. Anticipate attending [ADDRESS_648476] for the community is to go out and meet people 
where they are already gathering. It also minimizes the risk of low turn -out at meetings 
scheduled de novo and increases the investigators’ exposure to a variety of comments.  
In this method of community consultation, members of the study team, sometimes 
accompanied by [CONTACT_503765], ask to 
present and discuss the study at a regularly scheduled meeting of a relevant community 
group.  
For each group, we propose the following:  
 
• A study team member will be pre sent to answer questions from the  community.  
• Presentation will be clear, use of video/handouts depending on the venue, and be 
brief  
• If a presentation is longer than 15 minutes, it will be  interactive.  
• We will consider who the best person is to present to each  group.  Community Consultation Activities  
51  • Study team will be available for at least 30 minutes depending on how much time we 
are allocated (10 minutes to present, 15 minutes for discussion, and 5 minutes to 
hand -out and get back evaluation surveys).  
• Study team will probe for discussion using open- end questions.  
• Study team will ensure that the discussion includes feedback from  the participants on 
EFIC.  
• No monetary incentive to participants will be  offered  
 
A survey for group participants to indicate their thoughts, feelings, and opi[INVESTIGATOR_503742], anonymously, will be handed out and collected 
back at the end of the event. Study staff should allow at least five minutes at the end 
of the event for attendees to complete the  
 
We propose to contact [CONTACT_503766]/or mail about presenting at 
their meetings, with the goal of holding 3 -5 events total:  
• Ann Arbor Community  Foundation  
• Ann Arbor City  Council  
• Business groups  
• Ann Arbor Police  Officers  
• Ann Arbor YMCA  
• Faith -based  organizations  
• Neighborhood Residential  Associations  
• Retiree  groups  
• UMHS  Groups/Programs  
o Support group meeting for patients and families at the Frankel 
Cardiovascular Center  
o Patient and Family Centered Care  (PFCC) 
 
2. Survey Methods  
Based on our experience with other EFIC research studies, we believe an interview 
style, two -way dialogue discussion and address any questions, followed by a well- 
designed structured survey is an effective method  of communication.  Our experience 
revealed that respondents are more apt to understand complex research concepts, 
such as randomization, informed consent, EFIC, surrogate, etc, when specific examples 
are given.   We also believe this method can be used to reach large numbers and a 
wide variety of respondents including, individuals at risk of cardiac  arrest.  
A member of the research team will provide ample information to the survey 
respondent, and the survey will provide detailed information about EFIC regulation and the EROCA study.   We anticipate conducting 50 -75 surveys . 
52  We propose visiting the following:  
 
A. Cardiology Clinic – community at  risk 
We will approach adult patients and family members in the UMHS clinic to 
participate in our survey. If the participant agrees, verbal consent will be obtained 
and proceed with the interview. We will ensure that their participation does not 
interfere with patient care. Each survey will be take approximately 7 -10 minutes to 
complete and will be initiated by a trained clinical research coordinator (CRC) 
delegated by [CONTACT_978].  
B. Emergency Department – community at risk, geographic location, at risk 
population. Adult stable patients in the UMHS emergency department and their family members will be  approached.  
 
Completing a survey will suffice as implied consent. We will ensure that their 
participation does not interfere with patient care. Each survey will be take approximately 7 -10 minutes to complete and will be initiated by a trained clinical 
research coordinator (CRC) delegated by [CONTACT_978]. Members of the study team will identify potential participants from the ED electronic tracking board. A study team member or research coordinator will approach the patient and/or family member 
for their willingness to complete the survey. If the participant agrees, ver bal 
consent will be obtained and proceed with the interview.  
 
C. Set up EFIC/EROCA table if feasible at one or more events in Ann Arbor so community members can learn about the study and complete a survey if they 
choose.  Examples of events  include:  
a. Health Fairs 
b. Sporting  events  
c. Concerts and performing arts  events  
d. Festivals and Art  Fairs 
 
3. Use of a study website that has capacity to solicit and receive  comments  
Included could be  a  streamed generic emergency research video from the NETT  
 
https://nett.umich.edu/patients -communities/community -videos  
 
4. Opt-Out Mechanism  
Prior to and throughout the duration of the clinical trial, patients and their families will 
have various methods through which they can refuse participation in the trial. We will 
include this information at the community consultation meetings and on the brochures 
and posters for  public  disclosure.  We will provide “File of Life” magnets, driver’s  licen se 
[ADDRESS_648477] a link on our website to mail if 
requested. If a medical bracelet (wrist band) is preferred, one will be provided with instructions that it must be worn throughout the study duration.  
EMS pr oviders are accustomed to looking for medical information, typi[INVESTIGATOR_94954] a “File of 
Life” posted to the refrigerator or the back of the door and if outside their home, their wallet is searched for identification and any  medical history.  We will provide “File of Life” 
magnets, stickers, wrist bands, and cards at community events and have a link on our 
website to mail if  requested.  
If a family member is instructed about the study and declines, the patient will not be 
included in the study and standard CPR protocols will be followed. This will be carefully covered in EMS training.  
Community Consultation Mechanics  
Once community consultation meetings are scheduled, IRB will be notified and members are encouraged to attend the meetings, if available.  
 
All attendees, interviewees, and those who access the website will be asked to 
complete an attendance record, including their demographics. Only IRB approved handouts will be available to all attendees and should be in provided in an understandable language. O pt out procedures will be documented and included in 
the handout.  
 
Responses from the three forms of community consultation will be compi[INVESTIGATOR_503743].  
 
Presentation Materials  
All presentation materials, including  scripts, survey, and educational materials 
presented in this plan have been developed with input from members of the 
Neurological Emergencies Treatment Trials (NETT) , who have quite a bit of experience 
conducting community consultation and public disclos ure. 
 
 
 
All community consultation activities will be reported to the IRB, including the 
responses required written survey questions. Proposed timeframe to complete the community consultation activities is 4 months.  
A summary of the community consultation will include information about: the 
participants, the presentation, community questions and comments, and responses to 
closed - and open- ended questions.  Reporting Community Consultation  
54  Catchment area information will be collected as per the IRB. This information will allow 
the research team to concentrate its consultation and announcement efforts on the 
appropriate communities.  
 
Public Disclosure requirement of the Exception from Informed Consent (EFIC) regulations ( 21 
CFR 50.24) for emergency research, states:  
21 CFR 50.24  
(a)(7)Additional protections of the rights and welfare of subjects will be provided, 
including at least:  
 
(ii) Public disclosure to the communities in which the clinical investigation will be 
conducted and from which the subjects will be drawn, prior to initiation of the clinical 
investigation, of plans for the investigation and its risks and expected benefits;  
(iii) Public disclosure of sufficient information following completion of the clinical 
investigation  to apprise the community and researchers of the study, including the 
demographic characteristics of the research population, and its  results;  
Public disclosure will be done prior to enrollment and continue throughout the study period 
and after the study  has completed.  The study team will provide updates prior to  and during 
the study period, and after the study has completed. The study results will be distributed locally  and nationally  through peer -reviewed  journals,  and presentations  at national  meetings.  
Public disclosure is defined as the “dissemination of information about the research sufficient 
to allow a reasonable assumption that communities are aware of the plans for the  
investigation, its risks and expected benefits and the fact that the study will  be conducted”. It 
also includes “dissemination of information after the investigation is completed so that communities and scientific researchers are aware of the study’s results”.  
Appropriate public disclosure includes:  
 
• Clear statement  that informed  consent  will not be obtained  for any subjects  
• Information about the study medications use including a balanced description of  the 
risks and  benefits  
• Synopsis of the research protocol and study  design  
• How potential study subjects will be  identified  
• Participating  sites/institutions  
• Description of the attempts to contact a  LAR 
• Suggestions for opting out of the  study  PUBLIC DISCLOSURE  
55    
 
 
Using several different channels of communication for public disclosure increases the 
likelihood of reaching more of the intended audiences. It also can increase repetition of the 
message, improving the chance that intended audiences will be exposed to it often enough to 
absorb it.  For these reasons, we will use a combination of channels.  
Our p lans for implementation include:  
 
1. In-hospi[INVESTIGATOR_503744], to include, the Emergency Department, Cardiology Clinics, employee areas, and any other are 
identified as relevant, before and dur ing the trial. We will also utilize email messaging, 
to include  M Headlines, M Research, The University  Record,  etc. These  materials  will 
provide a description of the study, local contact [CONTACT_3031], study website address, 
and opt- out information.  All materials will be reviewed by [CONTACT_129730]. 
2. Community  Activities  
Obtain a booth/table at various local community events and hand out brochures 
and/or flyers describing study with contact [CONTACT_503767]. We will target groups that appear to have interest in healthcare and/or 
cardiac disease, such as health fairs, American Heart Association (Ann Arbor), and organized walk/runs in the area as well as any other event where community members may gather in large numbers, such as libraries, sports facilities, concerts, fairs and festivals.  
 
 
3. Electronic  Resources  
Electronic -based education is a passive approach to disseminating information that has 
benefits and challenges. There is no way to accurately measure whether how  much of the 
community is reached by [CONTACT_15252]. Access may be limited to those segments of the 
population with regular computer access. Despi[INVESTIGATOR_503745], electronic study education is inexpensive to develop and maintain and offers continuous and anonymous input from the 
public.  
In collaboration with UMHS Department of Communication, we propose to advertise EROCA 
and EFIC in local appropriate websites and via paid social media advertising.  Public Disclosure Planned  
[ADDRESS_648478] and print media ensures dissemination of accurate 
materials to a wide audience. We plan to advertise in the paper and electronic versions of the 
local news papers.  
 
In collaboration with UMHS Department of Communication, a news release will be written and IRB approved prior to distribution to any media.  
 
Printed materials, including advertisements for publication in newspapers and magazines, brochures, and flyers will be reviewed and approved by [CONTACT_1201] . Advertisements will be purchased in both English language and foreign language newspapers as appropriate. All printed advertisements will provide a general description of the study, the national and/or local website address, as well as site contact [CONTACT_3031].  
 
We also plan to contact [CONTACT_503768], who may be interested in covering the study and EFIC. Investigator appearances on local, radio, television, or call -in talk shows can bridge the line between 
public disclosure and community c onsultation.  
 
Any local flyers or brochures distributed will reference EROCA study website as an additional resource 
for patients, families, and healthcare providers to get information as well as ask questions about 
EROCA.  
 
  
 
 
All Public Disclosure activities will be summarized into a report and submitted to IRBMED for 
review.  
Timeline for Community Consultation and Public Disclosure Activities  Reporting Public Disclosure  
[ADDRESS_648479] 2-weeks prior to the start of the 
proposed trial. Public disclosure will continue beyond the end of study enrollment and 
through disclosure of study results, and anticipate a 1 -3 year timeframe.  
Analysis and Presentation of Results From Community Consultation and Public Disclosure  
 
Reporting of community consultation results will be provided by [CONTACT_503769]. 
Summaries of the data will be reported to the FDA.  
Data collected regarding CC and PD will include the following elements:  
• Consultation methodology  used  
• Community type: geographic or  condition -specific  
• Participants involved: number and  demographics  
• Duration, content, format of information  presented  
• Free text log of comments, questions, and responses to open- ended  questions  
• Log of pre -determined closed -ended survey questions and responses  
 
The study team will review survey responses and group meetings in summary form, and 
general themes will be summarized. The results of all local community consultation efforts will 
be summarized and submitted to IRBMED for review. If appointed and if present at the focus 
group discussions, an IRB liaison will provide an in -depth review of the discussions and 
additional feedback to the IRB as needed. Summaries of public disclosure will be reported to 
the IRB prior to approval, and then at least annually or upon request from the IRB.  
A provision of the protocol has been made to allow participants who learn of the trial through community consultation or public disclosure or other means, and who would not want to 
participate if treated for a cardiac arrest, to opt -out of trial prior to such an event. Opt- out 
forms will be available on the Huron Valley Ambulance (HVA) and all community consultation interactions.  
Contact[CONTACT_503770] (LAR) or family members  
The federal regulations for contact [CONTACT_4007] a Legally Authorized Representative (21 CFR 50.24) 
state:  
(a)(7)Additional protections of the rights and welfare of the subjects will be provided, including, at least:  
(v) If obtaining informed consent is not feasible and a legally authorized representative is not reasonably available, the investigator has committed, if  
[ADDRESS_648480]'s 
family member who is not a legally authorized representative, and asking whether he or she objects to the subject's participation in the clinical investigation. The investigator will summarize efforts made to contact [CONTACT_503771].  
 
(b) The IRB is responsible for ensuring that procedures are in place to inform, at the earliest feasible opportunity, each subject, or if the subject remains incapacitated, a legally authorized representative of the subject, or if such a representative is not reasonably available, a family member, of the subject's inclusion in the clinical investigation, the details of the investigation and other information contained in the informed consent document. The IRB shall also ensure that there is a procedure to inform the subject, or if the subject remains incapacitated, a legally authorized representative of the subject, or if such a representative is not reasonably available, a family member, that he or she may discontinue the subject's participation at any time without penalty or loss of benefits to which the subject is otherwise entitled. If a legally authorized representative or family member is told about the clinical investigation and the subject's condition improves, the subject is also to be informed as soon as feasible. If a subject is entered into a clinical investigation with waived consent and the subject dies before a legally authorized representative or family 
member can be contact[INVESTIGATOR_530], information about the clinical investigation is to be 
provided to the subject's legally authorized representative or family member, if feasible.  
 
A procedure for prospective informed consent will be developed as is required by [ADDRESS_648481] either an LAR or other family members. In circumstances in which is it impossible to identify a LAR within the the rapeutic time frame, EFIC will be applied.  
Participants enrolled in EROCA under EFIC procedures and unable to consent, their LAR or family member(s) will be informed of the clinical investigation, including inclusion criteria at 
the earliest possible opportunity.  
Participants enrolled in EROCA with EFIC, or their LAR/family member(s), will be informed of 
study enrollment in the clinical investigation at the earliest possible opportunity.  
Participants admitted to the hospi[INVESTIGATOR_503746]. A study team member will speak with the senior clinician to determine the stability of the participant and the appropriate time for speaking with the participant, or if not alert and capable of making informed decisions, a LAR or family member. The study team member will approach  the 
participant(or LAR/family) to notify them about the participant’s enrollment under EFIC, provide information about the study, including continued enrollment.  
59  Participant’s rights, the responsibilities of the investigators, and answer any questions about 
the study. At that time, the patient or the LAR will be asked to provide consent for continued participation in the study. A written informed consent document will be used to document the decision to either continue in the study or to not participate any further. A copy of this form will be provided to the participant and another copy will be placed in the research record.  
Participants who do not wish to continue to participate will be excluded from all further aspects  of the study except for the collection of data required by [CONTACT_503772]. If informed consent is provided by a LAR or family member, we will approach the subject at the earliest possible opportunity to s eek 
prospective, written informed consent for continuing participation in the study, should they become capable of doing so.  
It is anticipated that the notification of participants of LAR/family member(s) will commonly 
take place in the hospi[INVESTIGATOR_79638] [ADDRESS_648482]’s case report form. 
Reports of these logs will be included in annual reports to the IRB.  
If a participant is enrolled into EROCA and dies before a legally authorized representative or 
family member can be contact[INVESTIGATOR_530], the investigators will send a letter with basic information 
about the clinical investigation, the subject’s inclusion, and contact [CONTACT_503773].  
Due to the high mortality rate with sudden cardiac arrest, we expect many participants will 
die prior to coming to the hospi[INVESTIGATOR_3491] a letter will be sent to their LAR and/or family memb er(s). If no contact [CONTACT_503774][INVESTIGATOR_503747], 
attempts will be made to locate one through an obituary search for a next of kin listing and if found, their contact [CONTACT_503775] -line address sites.  
For participants enrolled, who die prior to hospi[INVESTIGATOR_059], a letter will be sent to the  
participant’s LAR/family member. The letter will include information about the study, their enrollment under EFIC, information collected, no further participation, contact [CONTACT_45465].  
Description of Refusal of Participation Procedures (Opt -Out)  
Prior to and throughout the duration of the clinical trial, patients and their families will have various  methods  through  which  they  can refuse  participation  in the trial.  We will include  this 
information at the community consultation meetings and on the brochures and posters for public  disclosure.  We will provide “File of Life” magnets, stickers, and cards  at community 
events and have a link on our website to mail if  requested.  
60    APPENDIX B:  UMHS ED  ECPR GUIDELINES   
 
Extracorporeal cardiopulmonary resuscitation (ECPR) is standard practice in the University of 
Michigan Hospi[INVESTIGATOR_122066]. ECPR utilizes a venous -arterial extracorporeal 
membrane oxygenation (VA- ECMO) circuit built from several components including. These 
510K cleared devices may change based on the institutional practice of the hospi[INVESTIGATOR_503748].  
QUADROX -iD Adult diffusion membrane Oxygenator 
CentriMag Primary Console  
CentriMag Back -up Console 
CentriMag Motor  
CardioHelp System  
 
Inclusion/Exclusion criteria for ECPR  
Inclusion Criteria:  
- Age 18 -70 
- -Initial shockable (ventricular tachycardia or ventricular fibrillation) or witnessed pulseless 
electrical activity or witnessed  asystole  
- Anticipated interval from cardiac arrest onset (or 911 call) to establishing ECMO flow </= [ADDRESS_648483]  
1 
 
Exclusion Criteria:  
-Sustained return of spontaneous circulation (ROSC)  
 
-DNAR or DNI advanced directive  
 
- Goals of care exclude ECPR (DNAR/DNI, advanced directive, or family  discussion)  
- Contraindication to anticoagulation  2 
- Estimated BMI  >40 
- Advanced or life -limiting comorbid ity 3 
- Unable to independently perform ADLs at baseline  
- Treating physician and/or ECMO consultant feels that ECPR is futile  4 
 
(1) Potentially reversible causes of cardiac arrest include: ACS, refractory arrhythmia, myocarditis, massive PE, severe hypothermia, drug  overdose  
 
(2) Contraindications to anticoagulation include: Suspected or known  intracranial 
hemorrhage, traumatic arrest, significant active  bleeding  
61  (3) Advanced or life -limiting co -morbidities include: Stroke or CNS lesion with significant 
neurologic or cognitive impairment, liver cirrhosis including ESLD, ESRD, advanced 
COPD or other chronic lung disease, advanced or metastatic  malignancy  
 
(4) Indications of futility are subject to the gestault of the treating physician and/or ECMO 
surgeon, but may include: Septic shock multiorgan failure, hypoxemic arrest,  metabolic 
acidosis with pH <7.0, Lactate >15, ETCO2 <10 despi[INVESTIGATOR_503749], poor candidate 
for destination LVAD, artificial heart, or  transplant  
   
 
UMHS AES ECPR Protocol  
 
 
 
 
(1) Inclusion/Exclusion criteria per Appendix  1 
(2) Necessary resources will be determined case -by-case, with necessary available 
resources including: ECMO specialist or ECMO credentialed emergency department  RN 
dedicated to sitting pump until transfer to CVC; CVC  bed to be made available ASAP; 
ED and EC3 staffing/volume/capacity to care for ECPR patient; Availability of EC3 
Intensivist by [CONTACT_48052]  

62  (3) Initiation of ECPR includes femoral veno -arterial cannulation by [CONTACT_503776], as well as circuit and pump 
management by [CONTACT_503777] -credentialed emergency department  RN 
(4) Potential disposition destinations include: Cardiavascular center ICU; cardiac catheterization lab; and/or EC3, if EC3 intensivist and ECMO credentialed RN  available  
 
Standard data collected on cardiac arrest patients in UMHS AES  
For internal review, quality improvement, and education, the following data elements are among those routinely obtained in patients with cardiac arrest and post- cardiac arrest care 
delivered in AES:  
 
1. Time intervals, including time of arrest or 911 call, transport time, time of ED  arrival, 
down -time, duration of CPR, time of return of circulation or initiation  of ECPR  
2. Drugs and shocks  administered  
3. Method(s) and device(s) used for  CPR 
4. Method(s) and device(s) used for airway  management  
5. End-Tidal CO2  measurements  
6. Vital sign trends,  with  attention to diastolic  blood  pressure  measurements  when 
obtained invasively  
7. Ventilator parameters, including settings and dynamic  measurements  
8. Blood gas  results  
9. Cerebral blood flow index via “C -Flow”  device  
10. Method(s) of therapeutic hypothermia, when utilized  
11. Initial and subsequent cardiac  rhythms  
12. Return of circulation ECG  interpretations  
13. Bedside echocardiography images and  interpretations  
14. Cardiac catheterization  results  
15. ED, ICU, and hospi[INVESTIGATOR_7577] 
16. EEG and neuro -prognostication results, including head CT, MRI, SSEP, NSE  level, 
Neurology consultation documentation  
17. Cerebral performance category upon  discharge  
63  
  APPENDIX  C:  WASHTENAW LIVINGSTON  CARDIAC ARREST  GUIDELINES   
 
Cardiac Arrest – General  
This protocol should be followed for all adult cardiac arrests. Medical cardiac arrest patients 
undergoing attempted resuscitation should not be transported unless return of spontaneous 
circulation (ROSC) is achieved or transport is ordered by [CONTACT_503778].  
If an arrest is of a known traumatic origin refer to the Dead on S cene Protocol . 
If it is unknown whether the arrest is traumatic or medical, continue with this protocol. 
Patients displaying a Do Not Resuscitate order or bracelet – follow DNR Protocol . 
When an ALS unit is present, follow this general cardiac arrest protocol in conjunction with the 
protocol that addresses the indentified rhythm.  
Once arrest is confirmed, emphasis should be on avoiding interruptions in CPR.  
CPR should be done in accordance with current guidelines established by [CONTACT_198955]. 
 
Pre-Medical Control MFR/EMT/SPECIALIST  
1. Confirm  Arrest  
A. Assess for signs of normal  breathing.  
B. Check a carotid pulse for not more than [ADDRESS_648484] 2” in depth for adults.  
B. Compression rate at least 100 per minute (An FDA approved mechanical CPR device  operating 
at the manufacturer pre -set rate meets this rate  requirement).  
C. Avoid excessive ventilation (volume and  rate).  
4. Continue CPR with minimal interruptions, changing the rescuer doing compressions every [ADDRESS_648485]. After insertion, provide continuous CPR 
without pauses for ventilation. Ventilations should  be 
EROCA – IDE Protocol Version 0.[ADDRESS_648486] 
Procedure.  
8. Verify CPR quality frequently and anytime the rescuer providing compressions or ventilations 
changes.  
9. If Return of Spontaneous Circulation (ROSC) has not been achieved after three, two minute 
cycles of CPR and ALS is not available or delayed, contact [CONTACT_503779], initiate  transport.  